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Abstract 
Tissue engineering in the orthopedic field is mainly focused on the development 
and design of material to serve as a temporary extracellular matrix or scaffold to overcame 
the limitation of actual treatments. In fact, current treatments are based on autologous or 
autogenous bone grafts and as an alternative to these, metals and ceramics. The limitation 
of this kind of implants is related to shortage of autograft that can be obtained and to donor 
site morbidity; the possibility of immune rejection and of pathogen transmission from 
donor to host in the case of allograft; the poor overall integration with the tissue at the 
implantation site for the metal and ceramic. 
The aim of study is the development of biocomposite scaffolds for orthopedic 
applications, based on the combination of polysaccharides (mainly alginate, Alg) 
engineered with bioactive molecules and nano-hydroxyapatite (nHAp). The first step was 
the synthesis and characterization of the different components of the scaffold. The nHAp 
was synthesized with sol-gel method and the obtained crystals have been chemically and 
morphologically characterized by mean of Raman spectroscopy, X-Ray Diffraction and 
Transmission Electron Microscopy. All the collected results confirm the chemical 
composition of nHAp and information about the average dimension of crystals (120nm). 
The synthesized nHAp was used to produce composite hydrogels of Alg and nHAp. The 
porous structure was achieved through freeze-casting. The obtained scaffold was 
characterized with µCT (µComputed tomography) and confocal microscopy; the 
histomorphometric data were compared with the parameters of native tissue with an high 
level of similarity between trabecular bone and scaffolds structure. Subsequently, the 
scaffolds have been investigated for their cytocompatibility and the results shows high rate 
of proliferation of cells seeded into the scaffold. 
The modification with specific proteins or peptides of the backbone of a polymer 
can be an effective strategy to tailor and control cell attachment, migration, proliferation 
and differentiation. Incorporation of peptide motifs containing sequences that are 
recognized by integrin receptors, such as arginine-glycine-aspartic acid (RGD)-based 
sequences, are now a common strategy to enhance the biological properties as well as 
differentiation and proliferation of a variety of cells, including osteoblasts. Along the same 
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line, reducing bacterial adhesion is important since microorganism surface attachment is 
the first critical step in the development of implant-associated infections. 
To introduce bioactive molecules and antimicrobial agents, enhancing in this way 
the biological property of the scaffolds, Chitlac was exploited as vector. Chitlac is a 
lactitolated-derivative of chitosan that can be modified by chemical grafting of bioactive 
peptides like RGD and that can be use to produce and stabilize silver nanoparticles (nAg) 
with antimicrobial activity. By adsorbing the Chitlac on the scaffold’s surface we spread 
the bio-signal inside the structure to induce a specific cell reaction. Alg/nHAp scaffolds 
were coated with Chitlac-RGD and Chitlac-nAg, respectively, and on those, biological and 
antimicrobial in vivo tests were performed.  For both scaffolds we observed good 
cytocompatibility and, in the case of scaffold with RGD, an improved cell proliferation; 
moreover, the scaffold with nAg showed a high level of antimicrobial activity. 
According the results obtained from the previous cytocompatibility tests, 
preliminary cytocompatibility in vivo tests were performed. The animal model was New 
Zealand rabbit and the produced scaffolds were inserted into bone defects on femur. Post-
operatively, three fluorochromes were administered sequentially every week. After 5 
weeks the rabbits were sacrificed and all the implanted bones were analyzed using µ-CT 
and light and confocal microscopy. We observed a high level of osteointegration of the 
scaffolds and ingrowth of newly deposited structured lamellar bone inside them, indicating 
good osteoconductive properties. 
In conclusion, the developed scaffolds have suitable biological properties both 
bioactive and antimicrobial. The in vitro results shows a high level of citocompatibility for 
all the scaffolds studied and that the presence of Chitlac-nAg does not compromise the 
compatibility of scaffolds.  In the case of scaffolds modified with RGD the results confirm 
that the presence of bioactive molecule is able to enhance the healing process also with 
respect to the BAG (BioActive Glass) control.  
The findings of the present study revealed that the structures here developed could 
serve as promising filler for orthopedic application.  
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Sommario 
L’ingegneria tissutale in campo ortopedico si pone come principale obiettivo lo 
sviluppo e la progettazione di matrici tridimensionali temporanee in grado di supportare la 
crescita e la migrazione cellulare, col fine di favorire la rigenerazione del tessuto 
danneggiato.L’impiego di matrici sintetiche dovrebbe permettere il superamento delle 
limitazioni correlate all’impiego di impianti autologhi allologhi e di materiali metallici e 
ceramici. Le principali limitazioni associate a questo tipo di impianti sono: la difficile 
reperibilità di sufficienti quantita di osso nel caso di autotrapianto; la possible insorgenza 
di rigetto o infezione nel caso dell’allotrapianto; il basso livello di integrazione dei metalli 
e delle ceramiche.  
Lo scopo del progetto di tesi è sviluppare materiali compositi (scaffold) per 
applicazioni ortopediche, costituiti dalla combinazione di biopolimeri ingegnerizzati con 
molecole bio-attive e di componenti inorganiche (nanoidrossiapatite-nHAp). La nHAp 
sintetizzata con metodo sol-gel è stata caratterizzata per verificarne la composizione 
chimica e le dimensioni dei cristalli. Le analisi effettuate (Raman spectroscopy, X-Ray 
Diffraction and Transmission Electron Microscopy) confermano la natura chimica dei 
cristalli e indicano come dimensione media dei cristalli un valore di 120nm. 
La nHAp è stata utilizzata per produrre gli scaffold compositi. La struttura porosa 
degli scaffold è stata ottenuta attraverso graduale congelamento degli idrogeli e successiva 
liofilizzazione. Le strutture porose così ottenute sono state analizzate con µCt e 
microscopia confocale per ottenere parametri istomorfometrici. I valori ottenuti sono stati 
confrontati con quelli presenti in letteratura confermando un’elevata analogia tra la 
struttura degli scaffold e quella dell’osso trabecolare. Le matrici composite sono state 
testate per misurarne la citocompatibilità in vitro. I risultati mostrano degli elevati livelli di 
proliferazione delle cellule negli scaffold. 
La modificazione della struttura degli scaffold con molecole biottive può 
permettere un maggiore controllo dell’adesione, proliferazione e differenziamento 
cellulare. La modificazione con peptidi contenenti sequenze di riconoscimento per i 
recettori delle integrine, come la sequenza arginina-glicina-acido aspartico (RGD), sono 
comuni strategie per aumentare la  proprietà biologiche degli scaffold. Allo stesso modo, la  
riduzione dell’adesione batterica è un importante requisito perchè l’adesione batterica è il 
passaggio critico nello svillupo di infezioni perimplantari. 
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Allo scopo di incrementate le proprietà biologiche degli scaffold, quali adesività 
cellulare ed attività antibatterica, le matrici sono state modificate combinando all’uso 
dell’alginato, l’utilizzo di un derivato lattitolato del chitosano (Chitlac) . I gruppi amminici 
primari della catena polisaccaridica del Chitlac sono stati utilizzati per l’ancoraggio 
chimico di un peptide d’adesione (a sequenza GRGDS) e per la formazione e 
stabilizzazione di nanoparticelle d’argento a proprietà antibatterica.  
Sfruttando la presenza di cariche opposte sui due polisaccaridi,  entrambe le forme 
di chitlac sono state adsorbite sulla superficie degli scaffold a base di alginato . Dai saggi 
in vitro emerge un evidente aumento della proliferazione cellulare sugli scaffold di Alg-
nHAp-RGD e un buon livello di citocompatibilità per gli scaffold contenenti 
nanoparticelle. Questi ultimi hanno inoltre evidenziato una spiccata attività antibatterica 
contro tutti i ceppi analizzati. 
Successivamente alla caratterizzazione in vitro degli scaffold, sono stati effettuati 
degli studi preliminari in vivo per testare i livelli di biocompatibilità delle matrici.Il 
modello animale scelto sono stati conigli New Zealand e gli scaffold sono stati inseriti in 
difetti ossei prodotti nell’osso femorale. Nel decorso post-operatorio, tre dversi 
fluorocromi sono stati somministrati ad intervalli settimanali. Dopo 6 settimane gli animali 
sono stati sacrificati i campioni di osso sono stati analizzati con µCT e microscopia ottica. 
Per tutti i campioni si osserva un buon livello di osteintegrazione con deposizione di 
metrice mineralizzata lamellare non solo al livello dell’interfaccia osso-scaffold ma anche 
all’interno della struttura porosa evidenziando buone capacità osteconduttive. 
Concludendo, le matrici sviluppate presentano promettenti proprietà biologiche e 
antimicrobiche. I risultati delle prove in vivo mostrano buoni levelli di citocompatibilità 
per tutti i campioni analizzati e che la presenza di nAg non compromette la 
citocompatibilità dei compositi. Nel caso degli scaffold modificati con RGD i risultati 
evidenziano un significativo aumento nelle proprietà rigenerative del materiali anche 
rispetto al controllo con vetro bioattivo. 
La somma dei risultati ottenuti permette di considerare i materiali utilizzati come 
promettenti riempitivi ossei. 
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1 Introduction 
1.1 Bone healing 
One of the most extraordinary properties of bone is its ability to heal with 
practically no scarring. This is possible because fracture healing is a complex process, 
involving a well-orchestrated series of biological events that follow a definable temporal 
and spatial sequence [1,2,3]. Bone healing is a multistage repair process which involves 
intramembranous and endochondral ossification at the molecular level [1,2,4,5]. During the 
process of fracture healing, molecular mechanisms repeatedly take place, that are known to 
regulate skeletal tissue formation during embryolonic development [6]. 
The regeneration processes that initiated in response to an injury must reestablish 
both original geometry and biomechanical competency of the damaged tissue structure.  
The molecular events that governing fracture healing are a complex network of 
signals comprising cell death, recruitment, proliferation, differentiation and tissue 
formation. Four components of the bone all contribute to the healing process, are located at 
the injury site, namely: cortex, the periosteum, the bone marrow, and the external soft 
tissue.  
The instructive interaction among cells occurs between the external soft tissues 
around the injured bone, the developing fields of endochondral bone, the intramembranous 
bone, and the underlying cortical bone and marrow [7]. The three potential sources of cells 
are the periosteum, the surrounding soft tissues, and the marrow space at the damaged 
cortical bone tissue.  The primary tissue sources of skeletogenic stem cells giving rise to 
callus are believed to derive from periosteum [8]. 
Numerous events are involved in the bone repair and the phases of fracture healing 
can be summarized as follows (Figure1-1) [2,7,9-11]:  
• hematoma formation:  hematoma formation is  a necessary step of healing 
Following a damage to the musculoskeletal system, disruption of vessels leads to 
activation of the coagulation cascade and formation of hematoma, which encompasses the 
fracture area. Hematoma removal significantly attenuates repair, as well as transplantation 
   2 
of hematoma produces new bone. [12,13] This can be traced back to the angiogenetic 
cytokines and vascular endothelial growth factors contained in the hematoma, which have 
the inherent capability to promote revascularization during bone repair [14,15]. Thus 
Hematoma formation represents a fundamental step of healing.  
• Inflammation: inflammatory cells are recruited to the site of injury. The 
inflammatory response is associated with pain, swelling, and the release of several growth 
factors and cytokines which have important roles both in the initiation of the repair cascade 
and in the bone remodeling by promoting cell recruitment and cell activation [7,9,10,16-
19]. 
• angiogenesis: the new blood vessels are formed from the pre-existing ones 
[20,21]. Angiogenesis is essential for bone repair since an inappropriate bone 
vascularization is associated with decreased bone formation and bone mass. During healing 
process a central role is played by osteogenic factors which are able to stimulate 
angiogenesis, either directly or through the induction of secretion of angiogenic molecules 
such as VEGF [7]. 
• callus formation: intramembranous ossification takes place to create an 
external callus. Intramembranous ossification directly forms bone without first forming 
cartilage from committed osteoprogenitor and undifferentiated mesenchymal cells that 
reside in the periosteum, situated away from the fracture site. Subsequently, the internal 
callus becomes mineralized with calcium hydroxyapatite, to form a hard callus of woven 
bone [7]. The ingrowth of vascular tissues into the developing callus proceeds with the 
development of the new periosteal bone and occurs from the proximal to distal edges 
where the periosteal response originates and progresses towards the fracture line. 
• bone remodeling: in the final remodeling phase, the large callus is replaced 
by secondary lamellar bone, and the vascular supply reverts to a normal state [7]. 
The time required to achieve radiographic healing, even under ideal circumstances, 
can take from 4 to 13 months, depending on the type of fracture and location of the injury 
[22,23]. The rate at which bony union occurs is also influenced by multiple factors related 
to patient compliance, fracture stability, nutritional status, and patient health [24-26]. 
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When this process is hampered, there is a risk of nonunion or delayed union between bone 
fragments, which can have a major impact on both the quality of life for the patient and the 
medical costs caused by prolonged or repeated treatments. 
 
Figure 1-1 The sequence of events that occurs during the process of bone healing. Hematoma 
formation and osteocyte necrosis due to hypoxia (A). This is followed by an inflammatory response in 
which various inflammatory cells are released with fibrin mesh formation (B). Later on, granulation 
tissue formation occurs, with fibroblast and mesenchymal cell migration and new capillary formation 
(C). Bone resorption is then followed by cartilage and callus bone formation (D and E). In this process, 
osteoid extracellular matrix (ECM) and matrix mineralization occurs. Finally, bone formation and 
remodeling occurs (F) [184]. 
1.2 Clinical needs in orthopedics 
There are roughly 1 million cases in the USA of skeletal defects a year that require 
bone-graft procedures to achieve union [28]. Socioeconomic consequences of treating 
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patients are a major concern for both USA and EU, and due the ageing of their population, 
they will increase in the next years. Most common current treatments are autologous bone 
grafts, autogenous bone grafts or, as an alternative to these, metals and ceramic based 
implant [28–32].  
The gold standard of bone replacement has been autologous bone graft that is when 
the bone is taken from another part of the patient’s own body. It is considered the gold 
standard because it provides osteogenic cells as well as essential osteoinductive factors 
needed for bone healing and regeneration [30]. It is commonly taken in the form of 
trabecular bone from the patient’s iliac crest, but cortical bone can be used as well [28,30]. 
However, although it presents relatively good percentages of success, the spectrum of 
cases in which it can be used is limited by the amount of the autograft that can be obtained 
and due to donor site morbidity [28-31]. 
Allograft, that is bone taken from a donor, could represent an alternative. However, 
the rate of graft incorporation is lower than with the autograft, there is the possibility of 
immune rejection and of pathogen transmission from donor to host, and although 
infrequent, infections could occur in the recipient’s body after the transplantation [28–31].  
As an alternative to these two bone grafts, there are implants based on metals and 
ceramics [28]. However, both of them do present several drawbacks. Metals, for instance, 
although providing immediate mechanical support at the site of the defect, exhibit poor 
overall integration with the surrounding tissue. In addition, failure of the implant can be 
caused by infection of fatigue loading [28]. Ceramics have very low tensile strength and 
they are brittle preventing their use in locations of significant torsion, bending, or shear 
stress [28].  
An adequate bone replacement is yet to be found although it is urgently needed for 
full recovery of the patients. Autograft bone provides the best source for osteoprogenitor 
cells, growth factors, and a scaffold. But autograft is limited in supply, and is generally 
associated with another incision, dissection, and accompanying morbidity. 
Osteoconductive bone void fillers such as morselized cancellous allograft bone, polymeric 
scaffolds, and biodegradable ceramics each have their advantage and deficiencies; 
however, all these materials function as a scaffold only, without the ability to induce bone 
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formation. Osteoinductive growth factors are essential to bone growth and remodeling; 
however, exogenous growth factors are expensive, are given in large nonphysiological 
doses, may yield unpredictable clinical results, and may have significant adverse effects. 
Demineralized bone matrix contains a scaffold and variable amounts of several growth 
factors. Recently, the use of mesenchymal stem cells and osteoprogenitors, together with a 
suitable scaffold carrier has gained increasing attention. In combination with appropriate 
growth factors, it can provide all the necessary components for osteogenesis. Future basic 
and clinical research will define the indications and outcomes for new combination 
products for reconstruction of lost bone associated with revision total joint replacement.  
1.3 Bone tissue engineering 
Most of the severe injuries related to bone are still unrecoverable or not adequately 
treated. 
It is in this context that an emerging field of science called Tissue Engineering (TE) 
has been gaining notoriety in the last 10 years.  In 1993 Langer and Vacanti defined tissue 
engineering as a interdisciplinary field of research that applies the principles of engineering 
to biology and medicine towards the development of biological substitutes that are able to 
restore, maintain, and improve normal functions and to replace damaged tissue [32].  
The TE approach offers several potential advantages over traditional techniques, 
including overcoming deficiency of donor site morbidity, decrease in technical sensitivity 
of the repair, and most important, ability to closely mimic the in vivo microenvironment in 
an attempt to reproduce normal bone development. TE is based on biochemical and 
biomolecular knowledge of tissue formation and regeneration processes, with the aim of 
inducing the formation of new functional tissue, instead of implanting non-integrating 
implants [33]. Three elements are central in tissue engineering: 
• cells: three potential sources of cells are involved in bone healing: 
periosteum, the surrounding soft tissues, and the marrow space at the site of damaged 
cortical bone tissue. Marrow from a bone defect site has been shown to supply the 
osteogenic progenitor cells that lead to bone repair. However, the surrounding tissues may 
also be a significant source of these important cells and of the nutrients needed to generate 
new vascularised bone. Populations of multipotent mesenchymal stem cells have been 
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shown to reside within the fibrous connective tissue compartments of many tissues and 
organs, including muscle. Furthermore, it is accepted that the periosteum contains 
quiescent self-renewable osteogenic progenitor stem cell populations that can generate new 
bone. The primary tissue source of skeletogenic stem cells that give rise to the callus are 
believed to be from the periosteum. [12] Therefore, the surrounding tissues may play a 
significant role in bone regeneration by providing critical precursor cells and a neovascular 
network to the defect site. All these cell sources can be considered in TE. 
• 3-dimensional support: the scaffold is the matrix that provides the cells 
with a tissue specific environment and architecture. It serves as a reservoir of water, 
nutrients, cytokines, and growth factors. The scaffold will act as a temporary support for 
cell proliferation and extracellular matrix deposition, with consequent bone in-growth, 
until the new tissue is totally restored. 
• bioactive signals: biological recognition between cells and  matrix is bi-
directional and dynamic. The extracellular matrix (ECM) presents adhesion signals to cells 
[34]: chemical modification of polymer materials with entire ECM molecules or relevant 
peptides or glycan fragments can be used to mediate specific mechanisms of cell adhesion. 
Moreover, the combination of normally soluble cues with the synthetic ECM can provide 
further level of control over tissue morphogenesis [35]. 
1.4 Scaffolds 
The development of synthetic analogues to ECM (scaffolds) is a major research 
topic in the tissue-engineering field [36]. The first scaffolds for tissue-engineering were 
typically designed to exhibit a minimum level of mechanical support and regulate diffusion 
of the nutrients and waste products between the new tissue and surrounding host tissue. 
The third–generation biomaterials are meant to be new materials that are able to stimulate 
specific cellular response at the molecular level. These materials’ properties should merge 
with their ability to tight and stimulate specific cellular activity and behaviour. Temporary 
3D porous structures that stimulate cells’ invasion, attachment and proliferation, as well as 
functionalized surfaces with peptide sequences which mimic the ECM components so as to 
trigger specific cell responses, are being developed. 
The following properties have been defined as essential in a scaffold: 
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• Biocompatibility: this is referred to the ability of a biomaterial to perform its 
desired function without eliciting any undesirable local or systemic effects but generating 
the most appropriate beneficial cellular or tissue response in that specific situation, this 
concept covers also the optimization of the clinically relevant performance of the scaffold. 
• Porosity: scaffolds must posses an open pore, fully interconnected structure 
to facilitate the neo-vascularization of the construct from the surrounding tissue. The 
scaffolds should also exhibit adequate micro-porosity, in order to allow capillary 
ingrowths. Porosity and interconnectivity are also important for an accurate diffusion of 
nutrients and gases and for the removal of metabolic waste products. 
• Osteinduction: it is the process by which osteogenesis is induced. Primitive, 
undifferentiated and pluripotent cells are stimulated to develop into the bone-forming cell 
lineage.  
• Osteoconduction: it is the ability of a surface to permit bone growth on it or 
into pores. It is strictly related with the nature of material.  
• Osteointegration: it is referred to the direct contact between living bone and 
implant. Osteointegration is a direct anchorage of an implant to the bone tissue without the 
growth of fibrous capsule at the bone-implant interface. 
• Biodegradability: it is described as the ability of a scaffold to degrade into 
biocompatible and bioresorbable products at rate that matches new tissue formation; in 
such a way, by the time the injury site is totally regenerated the scaffold is totally 
degraded. 
Material composition, architecture, structure, surface properties, degradation 
properties, together with the composition of any added biological components must be 
considered for scaffold design. However it is also important to consider the changes of all 
this factors with time [37]. 
Successful constructs must have certain minimum biochemical and physical 
properties to be applied in specific sites. Scaffolds are required the sufficient initial 
mechanical strength and stiffness to replace the mechanical function of the diseased or 
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damaged tissue, which the construct aims at repairing or regenerating. Stiffness and 
strength should be sufficient at least to permit cell seeding on the scaffold in vitro without 
compromising scaffold architecture, and to support and transmit forces in an in vivo 
healing site. The scaffold material should be sufficiently robust not only to resist traction 
forces exerted, by cells seeded into the scaffold, but also to contraction forces, which will 
be invoked during wound healing in vivo. 
However, during the in vivo phase, external and internal fixation systems or other 
supports or restrictions on patient activity, may partially substitute in early-stage recovery 
such mechanical roles of the intended scaffold.  
In addition, the importance of maintaining free space around bone defects is well 
understood. If the soft tissue can be kept from filling the space, bone will have the 
opportunity to grow into in the protected empty space. Successful bone regeneration can be 
achieved when a high-strength and biodegradable composite scaffold with a fully 
interconnected architecture is used to maintain the space of a critical size defect and to acts 
at the same time as an internal fixation device. 
The maintenance of a sufficient structural integrity is critical as tissue remodelling 
is important for achieving stable biomechanical conditions and vascularisation at the host 
site. The degree of remodelling depends on the tissue itself (cancellous bone remodel in 3–
6 months while cortical bone in 6–12 months) and its host anatomy and physiology. The 
scaffold architecture has to allow for initial cell attachment and subsequent migration into 
and through the matrix and for mass transfer of nutrients and metabolites. Moreover, it 
should provide sufficient space for development and later remodelling of the organized 
tissue. In vitro, low porosity stimulates osteogenesis by suppressing cell proliferation and 
forcing cell aggregation. In contrast, in vivo, high porosity and pore size result in greater 
bone ingrowth. However, a highly porous architecture results in low mechanical properties, 
thereby setting an upper functional limit for pore size and porosity. Based on early studies, 
the minimum requirement for pore size was considered to be approximately 100 µm, due 
to cell size, migration requirements and transport. Because of vascularisation, pore size has 
been shown to affect the progression of osteogenesis. Small pores favour hypoxic 
conditions and induce osteochondral formation before osteogenesis occurs. In contrast, 
scaffold architectures with larger pores rapidly become well-vascularised and lead to direct 
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osteogenesis. In more recent in vitro and in vivo studies, pore sizes >300 µm and pore 
interconnections are recommended for sufficient vascularisation of the tissue- engineered 
grafts [37,38].  
In addition to these essentials of morphology and geometry, a construct must 
possess surface properties, which are most favourable for the attachment and migration of 
cell types of interest. External size and shape of the construct must also be considered; 
together with customization for an individual patient [39].  
A review of the current bone engineering literature suggests that the scaffolds 
should fulfil a range of minimal requirements [40-43]. The repair and regeneration of 
musculoskeletal tissues in particular of bone remains a demanding application. In these 
cases scaffolds need to have a high elastic modulus in order to provide temporary 
mechanical support without showing symptoms of fatigue or failure, to be retained in the 
space they were designated for and to provide the tissue with adequate space for growth 
[44]. Moreover, bone is able to remodel in vivo under physiological loading [45]. Based on 
these biological processes, it is a requirement that the degradation and resorption kinetics 
have to be controlled in such a way that the bioresorbable scaffold retains its physical 
properties for at least 3–6 months (e.g. 1–3 months for cell culturing and 1–3 months in 
situ). Thereafter, the scaffold matrix can start losing its mechanical properties and should 
be metabolized by the body without a foreign body reaction after 12–18 months [39]. The 
mechanical properties of the bioresorbable 3D scaffold–tissue construct at the time of 
implantation should match that of the host tissue as closely as possible. It should possess 
sufficient strength and stiffness to function for a period until in vivo tissue ingrowth has 
replaced the slowly vanishing scaffold matrix. Mechanical loading may directly affect the 
degradation behaviour; recent studies show that cyclic compressive loading of poly(D,L-
lactide-co-glycolide) (PLGA) matrix leads to changes in surface deformation and 
morphology, that compressive loading initially collapses and stiffens the polymer matrix 
[39]. As consequence, the decrease in molecular weight of the polymer is slowed down due 
to the reduction of surface area available for hydrolysis, until the matrix architecture no 
longer accommodates the mechanical loading and begins to lose its integrity. In the case of 
constructs that are subjected to extensive in vitro culture and implanted in a partially 
developed state, the intrinsic mechanical properties of the scaffold architecture guide cell 
proliferation and differentiation only up to the phase where the premature bone or cartilage 
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construct is placed in a bioreactor or is transplanted. The degradation and resorption 
kinetics of the scaffold are designed to allow the seeded cells to proliferate and secrete 
their own ECM in the static and dynamic cell-seeding phase (weeks 1–4), while the 
polymer scaffold gradually degrades, leaving sufficient space for new cell and tissue 
growth. The physical support by the 3D scaffold is maintained until the engineered bone or 
cartilage has sufficient mechanical integrity to support itself. However, as the scaffold 
matrix degrades, contractile forces developed by the differentiating tissue can result in 
stresses, which result in a significant decrease in the size of the construct, compared to the 
size of the original scaffold. The challenge for the in vitro-grown cell/tissue construct is to 
produce an implant with similar mechanical properties to those of the host tissue. 
In addition to considerations on scaffold performances based on a holistic TE 
strategy, practical manufacturing considerations arise. For clinical applications, it must be 
possible to manufacture the scaffold in a reproducible, controlled fashion, quickly and at 
an economic cost. A manufacturing process might be required to accommodate the 
presence of biological components; it might be necessary to allow cell seeding or to 
incorporate biomolecules, which may be soluble or heat-labile.  
1.5  Biomaterial for scaffold design  
The most important step, in the development of scaffold, is the selection of the 
optimal material to be used. This is because its characteristics will strongly affect the 
overall properties of scaffold. The range of applications in orthopaedic field is vast and 
includes different kinds of materials. 
Ceramics: they have been widely used in biomedical engineering and bone 
substitution to produce porous scaffolds [46-48]. They can be from natural origin (e.g., 
coralline hydroxyapatite-HA) or synthetic such as synthetic HA or β-tricalcium phosphate 
(β-TCP) [49]. Because of the osteoconductive and osteoinductive, properties of such 
material, they have been considered for bone tissue engineering applications. Several 
works [32,48-50] have shown that by using ceramics with or without bone marrow cells, 
good results in terms of bone regeneration could be obtained. However, these materials 
have some major draw-backs. First of all they are brittle and present low mechanical 
stability, which prevents their use in large bone defects. Furthermore, due to factors that 
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take place in vivo, such as osteoclastic activity, their degradation/dissolution rates are 
difficult to predict. This could represent a problem as a rapid degradation can compromise 
their already limited mechanical stability. At the same time, this would dramatically 
increase the extracellular concentrations of Ca and P, which can cause cellular death [51]. 
Concerning bone and dental TE, the most commonly employed ceramic biomaterials are 
Alumina (Al2O3), Zirconia (ZrO2) and several porous ceramics. These non-metallic 
inorganic materials have a limited range of formulations [52]. Both mechanical and 
biological properties are influenced by the microstructure of the material, which is highly 
dependent on the applied manufacturing process (maximum temperature, duration of the 
thermal steps, purity of the powder, size and distribution of the grains and porosity). 
Nowadays, one of the most popular applications of bioceramics is in the field of hip 
prosthesis. As an example, femoral heads and acetabular cups are made of high density and 
highly pure Alumina. Thise kinds of prostheses exhibited excellent wear rates, excellent 
corrosion resistance, good biocompatibility and high strength. This meant a significant 
improvement in relation to conventional polyethylene cups. In fact, the latter are 
responsible for wear debris release that induces a foreign body reaction and eventual 
osteolysis [52]. Nevertheless, ceramic materials components suffer from early failures due 
to their low fracture toughness. Therefore, important efforts have been made to improve 
the material quality by modifying the production processes and design requirements. 
In the last twenty years, much attention has been paid to hydroxyapatite (Hap). This 
is a ceramic material essentially composed of phosphorus and calcium. Its synthetic 
formulation – Ca10(PO4)6(OH)2 – resembles the crystalline bioapatite mineral which 
constitutes 45% by volume, 65% by weight of the mineral fraction of human bone [53-55] 
Hap powder has been used since 1920 with the aim of promoting bone consolidation [56]. 
This crystalline molecule was firstly used as a coating for metallic implants in order to 
improve the osteoconductive and osteointegrative properties of the prostheses [57-59]. The 
application to ostearticular titanium implants demonstrated that coating with Hap made it 
possible to achieve an excellent bone fixation. Hap is well known to be biocompatible, 
bioactive, osteoconductive, non-toxic, non-inflammatory and non-immunogenic. For all 
these reasons, Hap became an essential compound of bone implants, cements and 
scaffolds. Several papers have been reported on the role of Hap in orthopaedics 
applications [53,60-64]. Moreover, Hap has been used as an adsorbent during 
chromatography for purification and separation, since the surfaces of Hap have high 
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adsorption ability for many substances. Therefore, Hap has been considered as carrier of 
proteins or antimicrobial drugs. Adsorption and their slow release from Hap have been 
largely studied [53].  
Besides adsorption abilities, the surface features of nano-sized Hap have been 
investigated for the significant role of its unique functional properties of high surface area 
to volume ratio that is considered fundamental for cell-biomaterial interaction [65]. For 
this reason renovated interest has been focused on new formulations of synthetic Hap 
which led to crystals or aggregates in the range of the nanometric scale.  
Recently, a great attention has been focused on composites of nano-hydroxyapatite 
(nHAp) with natural and synthetic polymers [60-62, 66-69]. 
Biodegradable polymers represent an alternative to metals and ceramics, and are 
believed to be the ideal materials for bone TE [70-72]. These can be divided in two groups: 
natural and synthetic.  
A variety of synthetic biodegradable polymers has been extensively considered and 
used to produce tissue-engineering scaffolds. Their chemical versatility and processability 
vary according to their chemical structure and nature, and hence a direct comparison with 
the natural polymers can not be performed. The most widely used are poly(L-lactic acid) 
(PLLA), poly(glycolic acid) (PGA), poly(ethylene glycol) (PEG), polycaprolactones, 
polyorthoesters, polyanhydrides and polycarbonates [70]. They have the advantage of FDA 
approval and the possibility to co-polymerize. Co-polymerization and control of the 
molecular weight has given tissue engineers the flexibility to tailor the mechanical and 
degradation properties of a material for specific applications.  
Natural biodegradable polymers are those obtained from natural sources, either 
from animal or vegetal source. Among these we can mention collagen [80-82], chitosan 
[73-75], alginate [76-79], hyaluronic acid (HA) [83-85], and poly(hydroxybutyrate) [86-
87]. The main advantages of these materials are their low immunogenic potential, the 
bioactivity, and the capability of interacting with the host’s tissue. They show a very high 
chemical versatility, and in some cases a virtually unlimited source, as for starch, chitosan 
and alginate.  
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Alginate (Alg) was first described in 1881, by the British chemist E.E.E. Standford 
[88]. It is synthesized in large quantities by marine brown algae (Phaeophyceae) [89], and 
by bacteria belonging to the genera Azotobacter and Pseudomonas [90, 91]. Alg is an 
unbranched polysaccharide consisting of the two 1-4 linked sugar residues β-D- 
mannuronic acid (M) and α-L-guluronic acid (G) Figure 1-2.  
 
Figure 1-2 Molecular structure of alginate molecules. G: α-L-guluronic acid; M: β-D-mannuronic acid 
The monomers are arranged in a pattern of blocks along the chain, with homopolymeric 
regions (M and G-blocks) interspersed with regions of alternating structure (MG-blocks) 
[89,92,93]. A strong correlation between structural and functional properties exists in Alg. 
The intrinsic flexibility of Alg in solution increases in order MG > MM > GG [94], but the 
viscosity depends mainly on the molecular size [96]. By contrast, the selectivity for 
binding of cations and the gel forming properties varies strongly with the composition [94] 
and sequence [92,93]. It has been stated that divalent cations like Ca2+, Sr2+ and Ba2+ bind 
preferentially to G-blocks in a highly cooperative manner [97]. It is this selective binding 
to Alg which accounts for its gel forming properties. The high selectivity for G-blocks has 
been explained by the “egg- box” model by Grant [114], based upon the linkage 
conformations of the guluronic residues. The di-axially linked G-residues form cavities 
which act as binding sites for the divalent cations. Sequences of such sites bind to similar 
sequences in other polymer chains giving rise to the junction zone in the gel network. 
Recently, it has been suggested by Donati et al. [99] that G-blocks are not the only 
sequences involved in junction formation. Based on experiments with polyalternating Alg, 
mannuronan and Alg rich in G-blocks, it could be extrapolated that junction zones in the 
gel network could occur between MG/MG-blocks and between GG/MG-blocks.  
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Figure 1-3 Probable interaction between calcium ion and G residues. 
Alginate from brown algae is the basis for numerous applications in biotechnology 
and biomedicine, due to its water-binding, viscosity and gel-forming properties [95]. At 
present, Alg gels are being employed in several areas of drug delivery and tissue 
engineering [100] Alg represents an attractive material for the preparation of “biohybrid 
organs” and “micro-bioreactors” because its hydrated three-dimensional (3D) network 
allows cells to adhere, spread, migrate and interact with other cells [101]. 
Encapsulation in Alg matrix exploiting the ability to form cross-linked matrices 
involving the use of divalent cations, includes the paramount benefit to be a flexible 
technology allowing variations in concentration of polymer, Alg composition, bead size 
and cell seeding density. Alg-based systems have been widely tested for islet encapsulation 
and have been shown to provide immuno-isolation after the system transplantation, thus 
prolonging the survival of encapsulated islets [102-104] 
Chitosan is one of the most abundant organic materials, being second only to 
cellulose in the amount produced annually by biosynthesis. It is typically obtained by 
deacetylation under alkaline conditions of chitin. Chitin is an important constituent of the 
exoskeleton in animals, especially in crustaceans, molluscs and insects. It is also the 
principal fibrillar polymer in the cell wall of certain fungi. Chitosan is a linear 
polysaccharide, composed of glucosamine and N-acetyl glucosamine units linked by β(1–
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4) glycosidic bonds. The content of glucosamine is called the degree of deacetylation 
(DD). In general, it is considered that when the DD of chitin is higher than about 50% 
(depending on the origin of the polymer and on the distribution of acetyl groups along the 
chains), it becomes soluble in an aqueous acidic medium, and in these conditions, it is 
named chitosan. The DD also affects the biodegradability of this polymer, as for DD above 
69% a significant decrease in vivo degradation has been found [105]. In fact, for fully 
deacetylated chitosan, no susceptibility to lysozyme has been observed [106-107]. The 
main parameters influencing the characteristics of this polysaccharide are the molecular 
weight (MW) and DD. In particular, the cristallinity of chitosan, which depends on the 
degree of N-deacetylatin, influences the kinetics of degradation. Depending on the source 
and preparation procedure, chitosan’s average molecular weight may range from 300 to 
over 1000 kDa, with a degree of deacetylation from 30 to 90%. In its crystalline form, 
chitosan is normally insoluble in aqueous solution above the pH 7; however, in dilute acids 
(pH<6), the protoned free amino groups on glucosamine facilitate solubility of the 
molecule [106-107]  
Recently, there has been a growing interest in the chemical modification of chitosan 
in order to improve its solubility and widen its applications [105]. Derivatization by 
introducing small functional groups to the chitosan structure, such as alkyl or 
carboxymethyl groups [108-110] can drastically increase the solubility of chitosan at 
neutral and alkaline pH values. Substitution with moieties bearing carboxylic groups can 
yield polymers with polyampholytic properties [105]. Among the various methods of 
modification, grafting has been the most widely used. Grafting of chitosan allows the 
formation of functional derivatives by covalent binding of a molecule onto the chitosan 
backbone. Chitosan has two types of reactive groups that can be grafted, namely the free 
amine groups on deacetylated units and the hydroxyl groups on the C3 and C6 carbons on 
acetylated or deacetylated units. Recently different groups have shown that after primary 
derivation followed by graft modification, chitosan would obtain much improved water 
solubility, antibacterial and antioxidant properties [105]. Grafting chitosan is also a 
common way to improve other properties such as increasing chelating [111] or 
complexation properties [112], bacteriostatic effect or enhancing adsorption properties 
[105]. Although the grafting of chitosan modifies its properties, it is possible to maintain 
some interesting characteristics such as mucoadhesivity, biocompatibility and 
biodegradability [113].  
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Nowadays chitosan is receiving a great deal of interest for medical and pharmaceutical 
applications. The main reasons for this increasing attention are the intrinsic properties of 
this polymer. In fact, chitosan is known for being biocompatible allowing its use in 
different medical fields such as topical ocular application, implantation or injection [110]. 
Moreover, chitosan is considered as biodegradable because it is metabolized by certain 
human enzyme, especially lysozyme [112]. This latter is the primary enzyme responsible 
for the in vivo degradation of chitosan through hydrolysis of acetylated residues; other 
proteolytic enzymes have show low level of degradation activity on the molecule. 
Moreover, its degradation products are non-toxic, non-immunogenic and non-carcinogenic. 
Highly deacetylated forms may last several months in vivo; eventual degradation of 
polymeric chain produces chitosan oligosacchrides of variable length. A direct correlation 
between degree of deacetylation of the chitosan and cell adhesion has been reported [115] 
It has been demonstrated that chitosan acts as a penetration enhancer by opening 
epithelial tight-junctions [116]. Due to its positive charge at physiologic pH, chitosan is 
also bioadhesive, a property that determines an increase in retention at the site of 
application. 
Chitosan is often used as biomaterial in tissue engineering applications because of 
its structural similarity to naturally occurring glycosaminoglycans and of its degradability 
by human enzymes. The positively charged chemical groups of chitosan are responsible for 
electrostatic interaction with anionic glycosaminoglycans (GAGs), proteoglycans and other 
negatively charged molecules. This property is of relevant interest because a large number 
of bioactive molecules, such as cytokine/growth factors are linked to GAG (mostly with 
heparin and heparan-sulphate), and therefore a chitosan-GAG complex may retain and 
concentrate growth factors secreted by colonizing cells [107]. Moreover, the presence of 
the N-acetylglucosamine moiety on chitosan also suggests related bioactivities. In fact, 
chitosan oligosaccharides have a stimulatory effect on macrophage, and both chitosan and 
chitin are chemo-attractans for neutrophils both in vivo and in vitro. 
Host tissue response to chitosan-based implants has been widely characterized. In 
general, these materials stimulate a minimal foreign body reaction, with little or no fibrous 
encapsulation [117]. This immunomodulatory effect of chitosan has been suggested to 
stimulate the integration of the implant material with the host [118]. 
 17 
Chitosan also promotes wound healing and has bacteriostatic effects [105]. Studies 
have shown that chitosan can reduce the infection rate of experimentally induced 
osteomyelitis by Staphylococcus aureus in rabbits. It is believed that, cationic amino 
groups of chitosan associate with anions on the bacteria cell wall, suppresing its 
biosynthesis. Moreover, chitosan disrupts the transportation across the cell wall 
accelerating the death of bacteria.  
Chitosan is used as carrier for drug delivery, combining its intrinsic antibacterial 
activity with antibiotic bonding property [119]. When added to Hap and plaster of Paris 
(calcium sulphate) to obtain a composite for vancomycin or Phosphomycin release, the 
composite material is able to inhibit in vitro methicillin-resistent S. aureus for as long as 3 
months, a period compatible with the treatment of most orthopaedic infection [120]. 
Chitosan has been reported to direct the differentiation of osteoprogenitors cells and 
to support the adhesion of human osteoblasts and the expression of type I collagen by cells. 
These finding suggest that chitosan may be a desirable material for bone regeneration. 
To enhance osteoconductivity and mechanically properties of gels, chitosan has 
been blended with bioactive inorganic particles, such as Hap, or calcium phosphates, 
which induce the formation of apatite. These composites are usually processed to provide 
an in situ forming injectable gels or porous scaffolds. Porous chitosan–ceramic composites 
exhibited an enhanced compressive modulus and an increased strength, potentially 
allowing for the use of these composites under load-bearing conditions. 
Chitosan has been used as a scaffolding material in articular cartilage engineering, 
due to its structural similarity with various GAG found in articular cartilage [118]. 
Chitosan-based scaffolds can deliver growth factor to promote the growth and biosynthetic 
potential of chondrocyte.  Lee et al. reported on porous collagen/CS/GAG scaffolds loaded 
with TGF-β1. This scaffolds exhibit controlled release of TGF-β1 and promoted cartilage 
regeneration [121]. 
In addition, cells within composites demonstrated in vitro high expression of bone 
specific genes and deposition of mineralized phases. Alternatively, specific growth factors 
(e.g. BMP-7 and PDGF) have been immobilized in chitosan gels to enhance their 
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osteoconductivity. Release of growth factor was mainly controlled by the degradation of 
gels and regeneration of bone tissue in the defects site was demonstrated. 
Chitosan has been combined with a variety of delivery materials such as alginate, 
hydroxyapatite, hyaluronic acid, calcium phosphate, PMMA (Polymethyl methacrilate), 
PLLA (Poly-L-lactic Acid), and growth factors for potential application in orthopaedics. In 
conclusion, chitosan offers many possibilities for cell-based tissue engineering e.g. 
matrices for cell culture including gel sponges, fibres and porous composites of chitosan 
with ceramic or other polymeric material such as collagen or gelatine to adjust cell seeding 
properties and mechanical behaviour [122-123]. 
Chitlac 
One of the most interesting features of chitosan as biomaterial is connected with the 
presence of amino groups located on the glucosamine units. Chemical derivatization based 
on the reactivity of these residues leads to strong modification of the physico-chemical and 
biological property of the polycation. Derivatization examples include acylation [108], 
alkylation [109] and carboxymethylation [110].  
 
Figure 1-4 schematic representation of Chitlac 
In this scenario, our group has modified a highly deacetitylated chitosan by grafting 
lactose moieties on the free amino groups of the polymer to obtain the corresponding 
lactitol derivative by reductive amination. 
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A low charge, highly hydrophilic chitosan derivative was obtained, indicated with 
the term Chitlac. This synthetic glycopolymer exhibited the ability to induce chondrocyte 
aggregation leading to the formation of nodules of high dimensions (up to 0.5-1mm) within 
12-24 hours. It also showed the ability to stimulate the biosynthesis of markers typical of 
articular cartilage, such as type II collagen and glycosaminoglycans [124]. 
These findings seem promising in view of a possible application of Chitlac for the 
regeneration of articular cartilage. The localization of Chitlac at the plasma membrane of 
isolated chondroytes and its permanence at the same site also after nodule formation 
indicate that the process is mediated by a specific binding of Chitlac to cells, most likely 
through its β-galactose residues [124]. Further experiments demonstrated the role of 
galectin-1 as a molecular bridge between Chitlac and chondrocyte cell surfaces [125]. 
Galectin-1 is a member of the S-type galactose-binding animal lectins. The discovery that 
galectin-1 binds with high affinity to polylactosamine-containing ligands (such as laminin) 
and the co- localization of galectin-1 with laminin in extracellular matrix suggested that its 
major function could be to promote cell adhesion to glycoconjugates [126]. Finally, Chitlac 
was modified with RGD peptide and tested as coating for orthopaedic constructs 
demonstrating its ability to promote adhesion on osteoblasts [38]. 
1.5.1 Chemical modification of polymers 
 Simple chemical modification can transform biologically inert materials into 
bioactive materials that can actively direct cell biology and expand the range of properties 
available from traditional materials. Chemical modification of synthetic polymer materials 
with entire ECM molecules or relevant peptide or glycan fragments can be used to mediate 
specific mechanisms of cell adhesion, and the association of normally soluble cues (e.g. 
growth factors) ECM can provide a further level of control over tissue morphogenesis [38]. 
Some of the most widely utilized peptide fragments are cell adhesion domains of ECM 
proteins, such as arginine-glycine-aspartic acid (RGD) (derived from fibronectin) and 
tyrosine-isoleucine-glycine-serine-arginine (YIGSR) (derived from laminin), which are 
frequently coupled with amide linkages to carboxylic-acid-containing polymers using 
carbodiimide chemistry [128]. It has long been observed that the specific peptide used to 
modify the material as well as their density are critical because they dictate which specific 
surface integrin receptor is used by the cell for adhesion, how many bonds are formed 
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between the cell and substrate and the extent of subsequent intracellular signaling [78, 
129,130].  
In addition, recent studies have shown that the nanoscale organization of proteins or 
peptides decorating the material might also affect many aspects of cell behaviour, 
including proliferation, migration and differentiation [129-130], further demonstrating the 
importance of peptide presentation in dictating cell fate. For example, closely spaced 
nanopatterned islands of RGD ligands supported greater preosteoblast focal adhesion, 
kinase phosphorylation and cell spreading, whereas more widely spaced RGD islands 
supported pre-osteoblast differentiation [131]. The mechanisms underlying these effects 
are currently not fully understood. However, the development of new tools that are able to 
quantify the interactions between cells and specific ligands, as well as the traction forces 
exerted on these bonds [37], are likely to be pivotal in elucidating these mechanisms and 
contributing to a more rational design of cell–material interactions in the future. New tools 
have demonstrated that the type and amount of adhesion ligand, as well as the mechanical 
properties of the substrate, are of equal importance in controlling cell behaviour. For 
example, the use of a fluorescence resonance energy transfer-based technique revealed that 
the proliferation and differentiation of pre-osteoblasts on an RGD-modified matrix 
correlated to the magnitude of force that cells generated to cluster cell-adhesion ligands 
and that this was dependent on the mechanical stiffness of the adhesion substrate [131]. It 
appears that the fate of cells in growing tissues relies heavily on the adhesion ligands 
presented by the matrix, and the development of methods to functionalize materials with 
these molecules is central in recapitulating these matrix effects and supporting the growth 
of functional tissue [130]. The release of growth factors and morphogens that have been 
encapsulated in polymers to manipulate the fate of both transplanted and host cells is 
governed by diffusion through the polymer and polymer degradation [37]. For example, 
use of an alginate hydrogel to deliver vascular endothelial growth factor-A165 (VEGF-
A165) in a sustained manner enhanced blood vessel formation and tissue perfusion in a 
mouse ischemic hindlimb model more than using a bolus dose of VEGF [132]. The 
sustained release of VEGF was tuned by controlling the biodegradation of the hydrogel via 
a bimodal molecular weight distribution of alginate and by partially oxidizing the polymer 
chains [132]. Recently, materials have been further developed to enable the sequential 
release of factors that direct multiple steps of tissue formation [37]. 
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1.5.2 Implant-related infection controlling material 
Like other approaches of medical intervention, the insertion of prostheses can be 
associated with serious complications; infection remains the most common one. In fact, the 
major barrier to the extended use of implant devices is bacterial adhesion to biomaterials, 
which causes biomaterial-centered infection and the lack of successful tissue integration or 
compatibility with biomaterial surfaces.  
When a biomaterial is inserted into the body, a so-called “conditioning film” is 
deposited on the biomaterials surface which comes from organic matter present in the 
surrounding fluid. It mostly consists of adsorbed proteins and blood platelets; the 
composition of this organic matter is influenced by the physical-chemical and 
morphological properties of the surface. This represents an intermediate layer connecting 
the substratum and the adhering microorganisms and mediates the direct interaction among 
the latter two ones [133]. Microbial adhesion to inert surfaces is described in terms of both 
specific and non-specific interactions. 
The adhesion of bacterial cells to material surfaces and interfaces is the first step in 
bacterial colonization and can be followed by the maturation of a biofilm. The use of 
antimicrobial prophylaxis and a laminar airflow surgical environment has reduced the risk 
of intraoperative infection. Nevertheless adhesion-mediated infections are extremely 
resistant to antibiotics and host defences and frequently persist till the device is removed. 
In this scenario, because colonization of the prosthesis preludes to clinical 
infection, one important approach has been to coat the surface of the prosthesis devices 
with an antimicrobial substance.  
Several characteristics of the material surface have been proposed to affect the first 
stage of bacterial adhesion. These factors include surface roughness, stiffness, charge, 
degree of hydrophobicity, Lewis acid-base character, hydrogen bonding capacity [134], 
van der Waals forces and specific receptor-ligand interactions. 
Three main strategies have been pursued to limit or prevent colonization of material 
surfaces: [135]. 
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• Preventing bacterial adhesion or at least reducing the capacity of bacteria to 
achieve the adhesion stages. To this end both hydrophilic and ultra-hydrophobic polymer 
surfaces are being explored [136-139] 
• Development of a surface able to kill bacteria by contact, thus inducing 
death of bacteria that have adhered stably to a surface. In general it occurs via conjugation 
of a polymeric surface with antibiotic functional molecules like antimicrobial peptides 
[140] quaternary ammonium compounds [141], guanidine polymers [142], phosphonium 
salts [143] or the use of the polycations [141]; 
• Leaching from the material surface of biocide compounds which diffuse 
over time inducing bacterial death. Polymeric surfaces can be tuned to allow a controlled 
release of compounds like antibiotics [144,145], silver ions [146] and nanoparticles, or 
peptides [147]. 
Polymers are widely used for the design of antimicrobial surfaces on implant 
biomaterials. They can be synthetic, natural-derived or blended forms and can be used 
alone or in association with other materials or molecules to obtain composite materials. 
Surface modifications of interface polymers offer many possibilities to face the problem of 
biomaterials infections; in fact, polymeric materials engineered at the nano- and 
microstructure play a fundamental role in the design and creation of surfaces capable of 
influencing the attachment of both prokaryotic and eukaryotic cells [148,149]. Many 
efforts are devoted to develop polymer-based surfaces lethal to pathogens, especially to 
prevent biofilm formation on indwelling devices [141]. Although it is not always 
considered in antimicrobial studies, a fundamental aspect that must be taken into account 
when designing antimicrobial implantable materials active against prokaryotic cells 
(bacteria) is their biocompatibility. Implantable biomaterials should not cause cytotoxic 
effects towards eukaryotic cells of the surrounding tissues. The choice of the antimicrobial 
material is also related to the technique used for the modification of the biomaterial 
surface. 
Silver nanocomposites A large interest in silver-based nanocomposite is due to 
silver biocidal property [150,151]. 
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Silver-based medical products, ranging from topical ointments and bandages for 
wound healing to coat stent, have been proven to be effective in retarding and preventing 
bacterial infections [152]. 
There is an increasing interest towards the exploitation of silver nanoparticles 
technology in the development of new bioactive biomaterials, aiming at combining the 
unique antimicrobial properties of the metal at the nano-scale with the performance of the 
biomaterial [153-157]. 
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2 Aim of the study 
 Bone defects derived from tumours, infections, trauma, biochemical disorders, and 
abnormal skeleton development are the main challenges in orthopaedic field [158].  
Surgical reconstruction procedures based on the used of autografts, allografts, xenografts 
and metal prosthesis are currently used to treat most of skeletal defects.  However, all the 
strategies used for bone regeneration or bone replacement have many drawbacks which 
have led to the development and the study of new and improved methods for repairing 
bony defects [159, 160]. 
In this scenario one of the most promising approaches developed in the last years is 
the bone tissue engineering. This strategy is based on the premise that progenitor cells, 
capable of tissue regeneration and which resides in the surrounding tissue, can migrate into 
artificial 3 D matrixes able to sustain and promote their attachment and proliferation. The 
goal of tissue engineering is the total replacement of damaged tissue with new functional 
bone.  
This study aims to develop biocomposite scaffolds based on the combination of 
polysaccharides engineered with bioactive molecules and hydroxyapatite to be used in 
orthopaedic field as osteoconductive and osteoinductive fillers in the treatment of bone 
defects.
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3 Materials and methods  
3.1 Synthesis of nano-hydroxyapatite (nHAp) 
Preparation of nHAp was achieved following the indications reported 
elsewhere[191]. Briefly, nHAp was prepared by wet chemical method using CaCl2 
(Sigma, USA) and (NH4)2HPO4 (Sigma, USA) as Ca and P precursors, respectively. To 
precipitate stoichiometric nHAp, a 0.3 M aqueous solution of (NH4)2HPO4 was slowly 
added dropwise to a 0.5 M aqueous solution of CaCl2. The rotation speed of stirrer was 
adjusted to 1000 rpm and the reaction temperature was maintained at 60°C. The pH was 
maintained above 10 by adding concentrated NH4OH using an injectable syringe. The 
resultant precipitate was aged for 24 h under stirring. After aging, the obtained white 
precipitate was filtered and washed five times with distilled water until complete 
removal of ammonium chloride. Final precipitate was centrifuged at 10,000 rpm for 
10min and dried in oven for 24 hours at 120°C. The nHAp powder was finally pounded 
in a mortar several times in order to obtain a homogeneous powder. 
3.2 Preparation of Alginate and Hydroxyapatite composites (Alg/nHAp) 
Scaffolds 
Alg/nHAp composite scaffolds were prepared by mixing alginate 2% (w/v) and 
nHAp at different concentrations in water using a calcium release method. Alginate (FG 
=0.65; FGG=0.56; MW=130000) was kindly provided by FMC biopolymers ( 
Drammen,Norway).   A 3% w/v of nHAp powder was homogenously dispersed into a 
stirred solution of alginate in water, followed by the addition of GDL 60mM to release 
calcium ions from nHAp. Aliquots of the gelling solution were then cured in 24-well 
tissue culture plates (h=18 mm, Ø=16 mm, Costar, Cambridge, MA) for 24 h at room 
temperature to allow complete gelification. The hydrogels in the tissue-culture plate 
were then step-wise cooled by immersion in a liquid cryostat. Ethylene Glycol in water 
(3:1) was used as refrigerant fluid. Temperature was decreased step-wise from 20°C to -
20°C by 5°C steps with 30 min intervals for equilibration; the samples were then freeze-
dried for 24 hours to obtain porous scaffolds. For control experiments, pure alginate 
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gels (nHAp-free) were prepared by replacing nHAp with CaCO3 (corresponding to 
30mM of Ca2+); and were then processed as nHAp composite gels.  
3.3 Characterization of Hydroxyapatite powder 
TEM (Transmission Electron Microscopy, Philips EM-208) images were used to 
evaluate the average dimensions of the synthesised nHAp particles. Image analysis, 
after grey-levels segmentation, has been performed by means of Image Pro Plus 6.2 
software on the TEM micrographs. 64 TEM images were processed and was obtained 
an average dimension of the particles of 150 nm was obtained. 
3.4 Raman spectroscopy and microscopy 
Raman spectra of Alg/nHAp hydrogels were recorded with a Renishaw “inVia” 
Raman system at 514.5 nm laser excitation coupled to a Leica DMLM microscope using 
a 20X objective. A thermoelectrically cooled charge coupled device (CCD) camera was 
used for detection. 
3.5 XRD analysis 
Samples of both alginate and Alg/nHAp hydrogels were studied by means of X-
Ray diffraction technique (XRD) using a diffractometer (STOE D500, Siemens, 
Munich, Germany) with Cu Kα radiation (λ = 0.1541 nm), mono-chromatized by a 
secondary flat graphite crystal. The scanning angle ranges from 10° to 60° of 2θ, the 
steps were of 0.02 of 2θ and the counting time was of 2s/step. The current used was 20 
mA and the voltage 40 kV. 
3.6 X-ray micro-computed tomography (µ-CT) 
X-ray micro-computed tomography of samples was obtained by means of a cone-
beam system called TOMOLAB (www.elettra.trieste.it/Labs/TOMOLAB)(2). The 
device is equipped with a sealed micro-focus X-ray tube, which guaranteed a focal spot 
size of 5 microns, in an energy range from 40 kV up to 130kV, and maximum current of 
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300µA. As a detector was used a CCD digital camera with (49.9×33.2) mm2 field of 
view and a pixel size of (12.5×12.5) µm2.  
The samples were positioned onto the turn-table of the instrument and 
acquisitions were performed with the following parameters: distance source-sample 
(FOD): 100mm; distance source-detector (FDD): 400mm; magnification: 4x; binning: 
2x2; resolution: 6.25µm; tomographies dimensions (pixels): 1984x1024; slices 
dimensions (pixels): 1984x1984; number of tomographies: 1440; number of slices: 864; 
E=40 kV I=200 µA; exposure time: from 2 to 5 seconds. The slices reconstruction 
process achieved by means of commercial software (Cobra Exxim) started once the 
tomographic scan was completed and all the projections were transferred to the 
workstation. Input projections and output slices are represented by files (one file per 
projection and one file per slice) using arrays of 16-bit integers. Custom produced 
MatLab code has been used to get a proper segmentation of the slices using Otsu’s 
[183] method and to obtain numerical values of structural features like porosity, 
interconnection, pore and trabecular size by means of parallel plate model [179]. For the 
3D reconstruction of scaffolds and bone sample the collected data were processed using 
Osirix Medical Image software (version 3.6; www.osirix-viewer.com).  
3.7 Scanning electron microscopy (SEM) 
The structure of scaffolds was analyzed using a Leica-Stereoscan 430i Scanning 
Electron microscope. Freeze-casted samples were sectioned at various planes and 
directly visualized by electron microscopy after sputter-coating with an ultrathin layer 
of gold. Scaffolds seeded with cells were rinsed with 10 mM HEPES pH=7.4 containing 
10 mM CaCl2, 100 mM NaCl, 5 mM glucose and fixed with 10% glutaraldehyde in PBS 
for 1h at room temperature. Samples were then washed three times with water, 
dehydrated by step-wise treatment with ethanol and finally dried with a critical point 
dryer, sputter-coated with gold and visualized by electron microscopy. 
  28 
3.8 Preparation of Simulated Body Fluid (SBF) 
Evaluation of the in vitro scaffold stability was performed with SBF (3;4) with a 
pH of 7.40 and ion concentrations nearly equal to those of human blood plasma (Na+ 
142.0, K+ 5.0, Mg2+ 1.5, Ca2+ 2.5, Cl− 147.8, HCO3− 4.2, HPO42− 1.0, SO42− 0.5 mM). 
The SBF was prepared by dissolving reagent-grade chemicals of NaCl, NaHCO3, KCl, 
K2HPO4 ·3H2O, MgCl2·6H2O, CaCl2 in distilled water and buffering at a pH of 7.40 
with tris(hydroxymethyl)aminomethane (CH2OH)3CNH2 and 1.0 M hydrochloric acid  
at 36.5 ◦ C. 
3.9 Swelling and dissolution behaviour 
The swelling behaviour of the scaffolds was investigated upon exposure to 
deionized water and to Simulated Body Fluid (SBF). The specimens were cylindrical in 
shape with an average diameter of 16 mm and a thickness of 4 mm. The swelling 
behaviour was quantified by measuring the changes in sample weight as a function of 
sample immersion time in water and SBF. Wet weighs were determined after blotting 
with a filter paper to remove the surface water and the swelling ratio was calculated 
using the equation: 
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where Esr is the amount of absorbed water (weight percent) by the polymer 
matrix, Wd and Ws are the weights of the samples in the dry and the swollen state, 
respectively. The results were taken as the mean values of three replicates. 
Structural stability and integrity of the scaffolds in water was evaluated for 4 
weeks at 37°C under gentle stirring. The samples were immersed in 8 ml of deionized 
water. Wet weight was measured after 10 min equilibration, at 7, 14, 21 and 31 days of 
immersion after blotting on filter paper, respectively. Soaking water was changed after 
each measurement. Weight variation was calculated using the formula:  
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Weight variation (%) = [1 - (Wtn / W 10min)] X 100 
Where Wtn and W 10min are the wet weights of the samples at the defined time and 
after 10 minutes of swelling, respectively. 
3.10 Cell culture and seeding 
Osteosarcoma MG-63 (ATCC® Number: CRL-1427™) human cell line was 
cultured in DMEM supplemented with 10% FBS, 1% Penicillin-streptomycin/1% L-
glutamine at 37°C and 5% pCO2. Saos-2 (ATCC® Number: HTB-85™) human 
osteosarcoma cell line was maintained in McCoy's Medium with 15% FBS, 1% 
Penicillin-streptomycin/1% L-glutamine at 37°C and 5% pCO2.  
For cell seeding onto scaffolds, porous freeze-casted scaffolds produced under 
sterile conditions, were reswollen in 5 mM CaCl2 for 30 min under agitation and 
immersed in complete cell culture medium for 24 hours in 24-wells culture plates to 
ensure chemical equilibration. Osteosarcoma cells, suspended in 50 µL of medium, 
were loaded with a micropipette over the whole upper surface of the scaffold. After 4 
hours, the scaffolds were placed into fresh, sterile 24-well culture plates and 1 mL of 
complete medium was added. 
3.11 Confocal laser scanning microscopy (CLSM) 
Fluorescence labelled scaffolds were obtained by coupling alginate with 
rhodamine 123 [210] for visualization in the CLSM. Individual constructs were placed 
on a coverslip and mounted on the stage of an inverted microscope LEICA TCS SP2 
associated with a confocal argon-ion laser scanning microscope. Confocal data have 
been processed by means of Image Pro Plus 6.2 software extended with the 3D 
Constructor package. Laser excitation light was provided at a wave-length of 488 nm, 
and fluorescent emissions were collected at wavelengths between 510 nm and 580 nm. 
For image acquisition, an exposure time of 0.8 s was adopted with a binning of 2x2 on 
the charge-coupled device camera, yielding a pixel size of 1.46 µm.  
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3.12 Cell Proliferation and viability on Alg/nHAp composites 
The viability and growth rate of MG63 and Saos-2 osteosarcoma human cell lines 
on Alg/nHAp composites were assessed as a function of time using the MTS assay 
according to the protocol provided by the manufacturer (CellTiter Aqueous One 
Solution cell proliferation Assay kit from Promega). A cell suspension of 40×103 was 
seeded on sterilized scaffolds, incubated at 37 °C in a humidified air atmosphere of 
containing 5% CO2 and the MTS assay was performed in quadruplicate 1, 7, 14 and 21 
days from cell seeding. Briefly, after 4 hours of incubation with the MTS reagent in a 
humidified 5% CO2 atmosphere, the medium was collected from the scaffolds and 
absorbance was measured on an ELISA plate reader at a wavelength of 490 nm. The 
background absorbance obtained from an empty scaffold (blank) was subtracted from 
the sample values.  
3.13 Phosphatase alkaline activity (ALP) 
A 100×103 suspension of MG63 and Saos-2 cells respectively, was seeded on the 
scaffolds and maintained in culture in complete medium at 37°C in a 5% pCO2 
atmosphere. At different days, scaffolds were washed at RT for 30 min in a buffer 10 
mM HEPES pH 7.4 containing 10 mM CaCl2, 100 mM NaCl, 5 mM glucose and finally 
dissolved in a sodium citrate solution (50 mM sodium citrate, 100 mM NaCl, 10 mM 
glucose, pH=7.4). 
Cells were collected by centrifugation at 400×g and lysed in a TritonX-100 
solution (0.2% w/w TritonX-100 in 100 mM Tris/HCl buffer, pH=9.8). Enzymatic 
activity was measured in a solution of 6 mM para-Nitro-Phenyl-Phosphate and 1 mM 
MgCl2 in Tris-HCl 100 mM pH=9.8 after 60 min of incubation at 37°C. Absorbance 
was measured at 410 nm. The results were normalized for the amount of protein content 
in the cellular extract calculated by means of BCA method according to the 
manufacturer’s protocol (Sigma). All tests were performed in quadruplicate. 
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3.14  Surgery procedure 
The animal trial was conducted at the University of Trieste. The animals were 15 
skeletally mature female New Zealand White rabbits (average weight of 3.5–4.5 kg, 
Conelli snc, Arona NO, Italy). Care of the animals followed the ‘‘European convention 
for the protection of vertebrate animals used for experimental and other scientific 
purposes’’ (1999/575/EC) and the Italian regulation (D.L. 116, 1993). The animals were 
anaesthetized and two cortical holes of 2 mm diameter and 8 mm depth in each distal 
diaphysis of femur were drilled under continuous saline irrigation. Alg/nHAp implants 
and positive control material (PerioGlas®-[192]) were gently packed in the surgically 
created defects. The implants, positive and negative controls (untreated defect) were 
randomly positioned in the femur of the animals. After implantation, the subcutaneous 
tissue and skin were closed in layers with resorbable sutures. The animals received a 
postoperative pain medication and were allowed to move without any restrictions 
immediately after recovery from the anaesthesia. The duration of the trial was 6 weeks. 
After this time the rabbits were euthanized and the femur dissected and prepared for the 
analysis.  
3.15 Fluorochrome bone labelling 
During the post-operative course five fluorochromes were administrated to the 
rabbits to evaluate the kinetic of mineralized matrix deposition. The different 
fluorochromessolutio (calcein blue, xylenol orange, calcein, alizarine complexone and 
doxycycline) were adjusted to pH values of 7.2, sterilized by filtration and administered 
sequentially every week starting at day 3 by subcutaneous injection. Details on the 
fluorochromes are given in table 3-1.  
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TIME FLUOROCHROME DOSE 
3° week Xylenol orange (λ ex.440/570nm; λ em.610 nm) 90 mg/Kg 
4° week Alzarine red (λ ex. 530/580 nm; λ em.624-645 nm) 30mg/kg 
5° week Doxiciclina (λ ex.340-425 nm; λ em.580 nm) 50 mg/Kg 
Table 3-1 list of fluorocrome administrated administreted as a function of time 
3.16 Histological analysis 
Histological analysis was performed on explants from femur diaphysis treated 
both with Alg/nHAp scaffolds and with BioActive Glass powder (PerioGlas®) in order 
to provide evidence of different osteoconductive properties and resorption processes of 
the two materials. The histological analyses were performed on mineralized and 
demineralised samples. 
Mineralized samples were prepared by dehydratation through a graded series of 
ethanol and embedding in methylmethacrylate resin (E-30®, Prochima, Calcinelli, Pu). 
After polymerization, non-decalcified thin sections were prepared with a modified 
diamond blade saw microtome technique (Troncatrice Micromet Automatica Remet, 
Italy) and made thinner with diamond paper (thickness 200 µm) (paper no. from 180 to 
2400 MP200V®, Remet, Bologna, Italia). The sectioning was performed along the 
transversal axis of the implants. The slices were than stained with basic fuchsine and 
toluidine blu at constant temperature of 70°C. 
Demineralised samples were obtained by fixing in buffered 5% solution of 
formaldehyde (Carlo Erba, Rodaro, Milan) for four days at 4°C immediately after 
resection. After fixation agent removal and washing in running water, the specimens 
were decalcified with EDTA 19% v/v in aqueous solution, pH 7.4 (Fluka/Sigma-
Aldrich, GmbH, Milan) and then dehydrated in graded ethanols (Carlo Erba, Rodaro, 
Milan), cleared with xylene (J.T. Backer, Deventer, Holland) and embedded in paraffin 
(Sherwood Medical Co., St Louis, MO, USA). Sample cutting was performed with a 
2050 Supercut microtome (Reichert-Jung, Cambridge Instruments Inc, New York) and 
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sections were mounted onto albumin-coated slides (Carlo Erba, Rodaro, Milan). 
Histological sections were subjected to (i) conventional staining with Blue 8GX 
dissolved in 0.25M acetate buffer containing 0.05M MgCl2, pH 5.6, at room 
temperature, for 4 hours, and (iii) as in (ii) plus counterstaining with Hematoxylin-
Eosin. 
The samples were then analyzed by light microscopy (Leica MZ 16® Germany) 
and the images were obtained by means of a digital camera (Leica DFC 320®, Leica 
Microsystems DI, Cambridge). 
3.17 Confocal Laser Scanning Microscopy (CLSM) of ex-vivo sections 
Fluorochrome-labelled bone samples for tissue visualization in CLSM were 
obtained by post-surgery subministration of three fluorochromes. Individual mineralised 
sections prepared as described above were placed on the stage of an inverted 
microscope LEICA TCS SP2 associated with a confocal argon-ion laser-scanning 
microscope. Confocal data have been processed by means of Image Pro Plus 6.2 
software. Laser excitation light was provided at a wavelength of 488 nm, and 
fluorescence emissions were collected at wavelengths between 510 and 580 nm. For 
image acquisition, an exposure time of 0.8 s was adopted with a binning of 2 × 2 on the 
charge-coupled device camera, yielding a pixel size of 1.46 µm.  
3.18 Chitlac synthesis 
Chitlac (1-deoxylactit-1-yl chitosan, Cas registery number 85941-43-1) sample 
was synthesised according with the procedure reported by Yalpani [190] starting from a 
highly deacetilated chitosan (residual acetilation degree=11.3% Aldrich chemical Co. 
(U.S.A.)). Chitosan (500mg, 3mmol) was dissolved with stirring in a mixture (1:1; pH 
4.5) of methanol and 1% aqueous acetic acid (30 ml). To the resulting viscous solution 
of the polysaccharide was added under vigorous stirring (10-20ml) of the lactose 
containing compound (410 mg of lactose dissolved in 2 ml of acetic acid 1%, pH 4,5) 
and sodium cyanoborohydride (179 mg of BH3CN dissolved in 2 ml of methanol). The 
reaction mixture was mixture was left at room temperature for 24 hours.  
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Subsequently the solution was diluted with deionized water and dialysed 
exhaustively against distilled water (Spectrapore, MWCO 12,000) until the conductivity 
of the external solution was below 2 µS at 4°C. The solution was filtered with 0.45 µm 
(Millipore) filter and freeze dried. The molecular weight of Chitlac was estimated to be 
approximately 1.5 x 106. 
3.19 Chitlac silver nano-particle synthesis (Chitlac nAg) 
Silver nanoparticles were obtained by reducing silver ions with ascorbic acid in 
Chitlac solutions according to the following procedures: freeze-dried Chitlac was 
dissolved in deionized water to obtain solution with concentration 1g/l. Chitlac solution 
were mixed with AgNO3 solution to achieve a final AgNO3 concentrations of 1mM; the 
ascorbic acid  (C6H8O6) solution was added at final concentration of 0.5 mM. 
3.20 Chitlac-fluorescein synthesis 
Chitlac (200 mg) was dissolved in 67 ml of 0.5 M sodium carbonate buffer. 
Fluorescein-isotiocianate (FITC, Sigma (27 mg)) was dissolved in 7 ml of 0.5 M 
sodium carbonate buffer and added drop wise to the Chitlac solution. The reaction 
mixture was stirred overnight at room temperature, against NaHCO3 0,1M, and against 
deionized water until the conductivity of the external solution was below 2 µS at 4°C 
(Spectrapore, MWCO 12,000) for 12 hours [21]. All procedures were carried out under 
light protection. The FTC-The solutions was filtered trough 0,45 µm filters and freeze-
dried. 
3.21  Synthesis of Chitlac-(NCO)-RGD 
96.0 mg of Chitlac (0.26 mmol) were dissolved in 20 ml of 25mM MES buffer 
(pH 6.5). 68.0 mg (0.14 mmol) of peptide GRGDS (2 equivalent with respect to the free 
amino groups) (MW 490.47) were dissolved in 1ml of buffer and activated with 66.8 
mg (0.35mmol) of EDC (MW 191.7 g/mol) and 8.1 mg (0.07 mmol) of NHS (MW 
115.9 g/mol). The Chitlac containing solution was added and the mixture was stirred 
overnight at room temperature. The solution was dialized against deionized water and 
freeze-dried. 
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The functionalization was calculated by determinig the amount of arginine in the 
hydrolysed by capillary electrophoresis. 
3.22 Preparation of scaffolds embedding Chitlac-nAg  
 The colloidal solution of Chitlac-nAg [135] was sterilized by means filtration 
through a 0.2µm filter (Millipore). 1 ml of solution was added to each scaffold in a 24 
multiwell plate. The scaffolds were incubated overnight at room temperature and then 
washed extensively with deionized water to remove non adsorbed Chitlac. 
3.23 Indirect quantification of Chitlac adsorbed on scaffolds 
The amount of Chitlac adsorbed on the scaffolds and the deposition kinetic were 
evaluated by using FITC-labelled Chitlac. To this aim, each scaffold was immersed in 1 
ml of FITC-labelled Chitlac solution. At selected intervals, the solution was removed 
and the residual concentration of Chitlac in it was evaluated by means 
spectrofluorimetry (Perkin Elmer LS50B Luminescence Spectometer) through a 
calibration curve. A 498 nm excitation wavelength was used and the emission spectrum 
was recorded in the range 460-600 nm.  
3.24 Inductively Coupled Plasma - Atomic Emission Spectrometry 
The quantitative analysis of the silver concentration was performed by means 
of ICP-AES using a Spectroflame module E Optical plasma interface (OPI) instrument 
by SPECTRO (Germani). 
The total amount of silver nanoparticles in the scaffolds was measured upon 
treatment with aqua ragia (concentrated nitric acid and concentrated hydrochloridric 
acid-1:3). The scaffold was solubilized with 5 ml of aqua regia, under stirring condition 
for one hours at about 100°C, then filtered through 0.45 µm GHP acrodisc siringe filters 
(Pall Life Science, Ann Arbor, MI) and the volume adjusted to 25 ml with deionized 
water. Each test was performed in triplicate. To evaluate the amount of nAg released 
from nAg scaffolds they have been stirred for 24h in 3 ml of washing solution (NaCl 
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0.015 M); after incubation for different times, supernatant from the scaffolds was 
removed and 1 ml of aqua regia added to prevent metal reduction.  
The washing solution was changed every 24 hours with the aim to maximize 
the ion exchange and evaluate the structural stability of scaffolds. The amount of silver 
was collected after centrifugation of the samples and filtration with a membrane of 
Teflon 0,42µm (by Millipore-USA). The obtained value has been compared with a 
calibration curve calculated with a standard solution of silver (Silver ICP/DCP -Sigma 
Aldrich) 10,000 µg/ml in HNO3. The used wavelength was 328.068 nm and with a 
detection limit of 0.02mg/l.  The coefficient of correlation was higher than 0.998. 
3.25 Antimicrobial efficacy of Chitlac-nAg scaffolds  
The antibacterial activity of Chitlac-nAg scaffolds was evaluated using 
cultures of E.coli (ATCC25922), S.epidermidis (clinical isolate), S.aureus 
(ATCC252922), and P.auruginosa (ATCC 27853).   
 Bacterial suspensions were prepared by adding 20 µl of bacteria, preserved in 
glycerol, to 5 ml of LB (Luria-Bertani) or MH (Muller- Hinton) broth. The obtained 
suspensions were incubated o/n at 37°C. After 24 hours, 500µl of bacterial suspension 
was diluted in 15ml of broth and grown for 60-90 minutes at 37°C. Bacterial 
concentration was measured by means of optical density (O.D.) spectrometric 
measurement at 600nm. The number of bacteria/ml was calculated according to the 
following equation: 
0.031 : 4.6∗107 = O.D. : X 
The bacterial suspension was diluted in PBS (phosphate buffered saline) to 
obtain a final concentration of 106 bacteria/ml. In a 24-multiwell plate, 1 ml of bacterial 
suspension was added to each scaffold. The plates were incubated at 37°C under 
shaking for defined times. At the end of incubation, the bacterial suspension was 
transferred in a 15ml tube and the scaffolds were washed with 1 ml of PBS by vortexing 
for 30 seconds. The washing solution was then added to the bacterial suspension 
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previously transferred into the tube. The total collected bacterial solution was serially 
diluted in PBS (from 10-1 to 10-6) and plated in duplicate on MH agar. After incubation 
ON at 37°C the Colony Forming Units (CFU) were counted.  
3.26 Animal model for antibacterial tests  
The experiment was performed with nine adult male Sprague–Dawley rats 
(Harlan, Horst, The Netherlands) weighing a mean of 281 g (SD 15 g) as pilot study. 
The aim was to investigate the capability of bacteria to induce infection and biofilm 
formation on cement specimens inserted in the medullar cavity of the metaphyseal area 
of tibia. Before surgery, the rats were acclimated to their new environment and fed a 
standard laboratory diet. The local Animal Welfare Committee and the Provincial State 
Office of Western Finland approved the study protocol (Reg. No. 1436/04 and 
1539/05). 
3.26.1 Preparation of bacterial suspension  
Three different concentrations (10^6, 10^7 and 10^8 CFU/ml) of a clinical strain 
of S. epidermidis were used. Every bacterial suspension was aliquoted in two test tubes. 
In one of them a bone cement cylinder (Palacos R-40; Heraeus) (size 2 x 3 mm) was 
immersed approximately for 12-16 h. From the other test tube, 0.05 ml of bacterial 
suspension was collected and directly injected into the medullar cavity. 
3.26.2 Surgery procedure 
The animals were anesthetized by subcutaneous injection of ketamin 
hydrochloride (Ketalar; Parke-Davis, Barcelona, Spain) and medetomidine (Domitor; 
Orion Pharma, Espoo, Finland). Skin preparation involved careful shaving and 
scrubbing with 20% chlorhexidine (Klorhexol, Oy Leiras Ab, Turku, Finland) followed 
by disinfection with 5% chlorhexidine and surgical draping. Using standard sterile 
surgical techniques the proximal metaphyseal area of tibia was exposed anteromedially. 
Under continuous physiological saline irrigation, a hole (diameter 2.8 m,) was drilled in 
the anteromedial cortex of tibia distally from the medial collateral ligament. A smaller 
hole (diameter 1.0 mm) was drilled 5 mm distally. Bone marrow between the cortical 
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windows was removed by rinsing with 0.9% saline through the holes. A volume of 0.05 
ml of 5% w/v sodium morrhuate (Scleromate, Glenwood, Englewood, N.J. 07631, 
USA) was injected to the medullary cavity. Immediately following this, 0.05 ml of 
bacterial inoculum was injected into the medullary cavity. In half of the animals tested, 
a bone cement cylinder preincubated with the bacterial suspension was inserted into the 
medullary cavity. In the others, a sterile bone cement cylinder was placed. Soft tissues 
were closed in layers and the anaestehesia was reversed by subcutaneous injection of 
antipamezol (Antisedan). Standard postoperative pain medication of subcutaneous 
buprenorphine was administered for three days after surgery. The animals were allowed 
free unrestricted weight bearing after recovery of anaesthesia.  
3.26.3 18F-FDG PET imaging 
PET imaging analysis was performed with an Advance PET scanner (General 
Electric Medical Systems, Milwaukee, WI, USA) operating in two-dimensional mode 
(high resolution). The scanner has 18 rings of Bismuth germanate detectors, and the 
axial length of the imaging field of view (FOV) is 152 mm.  
The animals underwent PET-scan four weeks after surgery. They were 
anaesthetized according to the protocol employed for the surgery procedure. A   
combined PET-CT analysis was performed. After PET, the animals were sacrificed with 
euthanasia by overdose of CO2. 
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4 Results and discussion  
4.1 The inorganic component: Hydroxyapatite 
4.1.1 Characterization of hydroxyapatite 
In the present work a nanometric form of hydroxyapatite (nHAp) prepared by wet 
chemical method [161] was employed. In order to characterize the physical-chemical 
properties of the nHAp several analyses were carried out. TEM images were used to 
evaluate the average dimensions of the synthesised nHAp particles. 64 TEM images 
were processed leading to the result of an average dimension of the particles of 120 nm 
(Figure 4-1). The distribution range of particles dimension was between 0.05 and 0.2 
µm.  
 
 
Figure 4-1: Image analysis on TEM micrographs of nHAp particles. 
Chemical characterization of the nHAp powder was achieved by means of Raman 
spectroscopy. Figure 4-2 reports the Raman spectra of commercial Hap (Fluka, Sigma 
Aldrich-HapF) and newly synthesized nHAp in comparison with a literature reference 
spectrum [183]. A perfect overlapping of the main characteristic peaks of the two 
individual compounds with those reported in literature was found. In particular, the 
following peaks were present: 
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•  432 and 442 cm-1, corresponding to the factor group splitting of the ν2 
bending vibrations of the PO43- ion; 
• 579, 592 and 608 cm-1 belonging to ν4 fundamental vibrational mode and 
arise from the triply degenerate bending vibrations of the PO43- ion; 
• The intense band at 962 cm-1 arising from the symmetric stretching 
modes and is designated as the ν1 fundamental vibrational mode of the PO43- ion; 
• 1025, 1047, 1075 and 1087 cm-1 arising from the ν4 fundamental 
vibrational modes due to the asymmetric stretching vibrations of the P-O bonds 
 
 
Figure 4-2: Raman Spectra of A): nHAp and commercial Hap; B): Literature reference (5). 
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Figure 4-3: XRD pattern of nHAp and HapF powders. 
The XRD pattern of the two Hap powders (Figure 4-3) shows all the main 
characteristic peaks present in the JCPDS reference file for Hap [163] Finally 
cytotocompatibility investigation was conducted on the nHAp powder using two 
different osteoblast-like cell lines (MG63, Saos-2), leading to the conclusion that there 
were no cytotoxic effects (data not reported).  
4.2 Biocomposite scaffolds for non-load bearing applications 
4.2.1 Casting and Characterization of composite scaffolds 
The main target of this work was to develop an isotropically homogeneous porous 
composite scaffold based on Alginate (Alg) and nHAp. The strategy devised to achieve 
this goal was based on the combination of two sequentially applied physical chemical 
processes. In the first one a homogeneous calcium-alginate gel is produced in water; in 
the second step the solvent is removed allowing the formation of pores as a result of 
solvent/solute phase separation.  
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Alginate is known to produce strong and stable gels with calcium. However, the 
polymer/ion affinity is so high that special precautions must be taken to avoid formation 
of randomly distributed zones of inhomogeneity. A homogeneous gel can be prepared 
only if calcium ions are uniformly released in a controlled way throughout the 
polysaccharide solution, instead of being directly added as external cross-linking agents. 
Lin et al. reported the preparation and characterization of an Alg/nHAp scaffold by 
blend mixing of the polysaccharide and CaCl2 solution with the homogeneity 
guaranteed by the use of a homogenizer [164]. However the main limitations of those 
constructs were a very low structural and morphological stability associated with the 
inability of the different scaffolds formulations to sustain cell viability and growth. In 
this work the hydrogels were prepared by means of a release of calcium ions from the 
inorganic component due to a slight environment acidification obtained by adding D-
glucono-δ-lactone. Various calcium salts can be used as reservoirs of Ca2+ ions for acid 
displacement [165]: we resorted to use nHAp itself for this purpose owing to its 
fundamental role of inorganic component of bone and its ability to interact with living 
tissues. The advantage of this “internal” gelation process resides in the slow hydrolysis 
of GDL hich provides for a delay time between the suspension of the lactone and the 
gelling of Alg, allowing homogeneous gel formation and casting of different gel shapes. 
Isotropic porous interconnected structures were obtained through a non-
directional freezing by immersion in a cryostat. Suitable pore size (100-300 µm) was 
achieved by setting the cooling rate: a temperature decrease from 20°C to -20°C by 5°C 
steps with 30 min equilibration intervals resulted to be the best in terms of structural 
features (Figure 4-4 A and B). For lower cooling rates the final microstructure was 
characterized by larger pores (> 500 µm) and, conversely, for faster cooling rate smaller 
pores were obtained (<100 µm) (data not shown). The constructs displayed a 
homogeneous and uniform distribution of the nHAp throughout the entire structure from 
the external to the internal part of the scaffold. The nHAp granules seem to be entrapped 
in the polymer matrix resulting in a very rough surface of the pore walls (Figure 4-4 C). 
At the highest magnification, the grain of the original inorganic component appears as a 
modulating factor of the roughness of the pores (Figure 4-4 D). 
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Figure 4-4 A): 20x SEM micrograph showing the uniform pore size distribution; inset: 3D 
appearance of the Alg/nHAp scaffold; B): 100x SEM micrograph of the interconnectivity feature of 
the scaffold; C): 200x SEM micrograph of the nHAp granules uniformly dispersed on the polymer 
matrix; D): 2000x SEM micrograph of the nHAp granules showing the coarseness of the inorganic 
component. 
 
A B 
C D 
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4.2.2 Physical-Chemical Characterization of Alg/nHAp composite 
To assess the chemical stability of Alg and in particular of nHAp and commercial 
Hap after the gelification process, the scaffolds prepared with Alg and Hap have been 
analysed from a chemical and crystallographic point of view by means of Raman 
spectroscopy and XRD, respectively. Direct comparison (assigned according to 
literature data ) of the powder of both Hap, commercial and synthesised,  and Alg with 
the corresponding ones obtained from the composite hydrogel displayed a perfect 
overlapping of the Raman peaks (Figure 4-5 A). Moreover, the possibility of scanning 
extended areas of the composite scaffold by Raman technique allowed confirming the 
uniform distribution of Hap along the bulk of the sample. XRD analyses were 
performed on the freshly prepared hydrogels for both Alg-CaCO3 and Alg/Hap 
compositions. As reported in Figure 4-5 B, the XRD patterns of the Alg/Hap hydrogel 
sample result to be the sum of those of the bare Alg hydrogel and of the Hap powders. 
  
Figure 4-5 A): Raman spectra of the Alg/Hap scaffold components: Hap powder (a), alginate 
powder (b), Alg/Hap freeze-casted scaffold (c). B): XRD pattern of the Alg/Hap scaffold 
components: Hap powder (a) 2%, Alg 30mM, CaCO3 60mM, GDL freshly prepared gel (b), 
Alg/Hap freshly prepared gel (c). 
4.2.3 Mechanical Characterization 
Scaffolds described in this thesis have been primarily developed to be employed 
as non-load bearing fillers for bone defects. Since stresses associated with implant 
surgery and physiological mechanical stimuli are much lower than those associated with 
load-bearing applications, the requirements in terms of mechanical properties are not 
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stringent. In general terms, compression moduli of about 10-20 MPa are considered as 
largely acceptable for such applications [10;11].  
Mechanical properties of composite scaffolds were assessed, on dry (scaffold) and 
wet samples (gel), by measuring their Young’s modulus (E) and Ultimate Compression 
Strength (σUCS) under uniaxial compression. 
The compression stress-strain curve of the polysaccharide-based composites was 
recorded and the Young’s modulus of the sample was obtained by means of a linear 
fitting of the stress-strain relationship between strain 0% and strain 0.5%. Moreover, the 
effect of the addition of nHAp on the mechanical properties of the nHAp-free samples – 
gels, freeze-casted and reswollen – was also evaluated. 
The mechanical parameters found for the present constructs (Table 4-1) were 
higher than those reported in literature for the polymeric scaffolds [12-15]. An increase 
of the mechanical features, E and σUCS, was observed following the addition of the 
inorganic compound with respect to the nHAp-free samples. In fact, the compressive 
modulus of the Alg/nHAp gels was 83.0 kPa whereas the one of the nHAp-free gels was 
20.0 kPa, corresponding to 315% increase. Along the same line, the compressive 
modulus of the Alg/nHAp freeze-casted samples (6.3x103 kPa) increased of 80% if 
compared with the nHAp-free scaffold (3.5x103 kPa). The Ultimate Compression 
Strength increased by 48%, rising from 230.1 kPa of the nHAp-free scaffolds to 341.2 
kPa of the ones with nHAp. Hydrated gels and reswollen scaffolds obviously show 
mechanical properties about a hundredfold lower than the corresponding dried forms. 
Nevertheless, the Young’s Modulus of reswollen Alg/nHAp scaffolds is about 340% 
higher than that of reswollen nHAp-free one (35.0 kPa vs. 8.0 kPa). 
  E (kPa) ΣUCS (kPa) 
Alg/nHAp 83.0 ± 9.0 - Gels Alg 20.0 ± 13.0 - 
Alg/nHAp (6.3±1.6)x103 341.2 ± 43.7 Dry Scaffolds Alg (3.5±1.3)x103 230.1 ± 31.4 
Alg/nHAp 35.0 ± 9.0 - Wet Scaffolds Alg 8.0 ± 2.3 - 
Table  4-1 Mechanical Properties of constructs. 
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4.3 Quantitative Three Dimensional Image Analysis 
Architectural features of scaffolds as well as their structural properties are crucial 
factors for a correct design of constructs used in tissue engineering fields. These three-
dimensional matrices are required to be highly porous to be vascularized and colonized 
by the cells of new tissue. The average pore size, the pore size distribution and the 
topology must be tailored to respond to specific applications requirements as they 
strongly influence cell adhesion, proliferation and matrix deposition, as well as the 
formation of blood vessels within the scaffold to help tissue ingrowth. 
While bioactive nHAp reinforcements exposed on the surface of a biocomposite 
promote a stable bone-scaffold interface, osteoconduction and osteointegration require 
the vascularization and growth of bone into the implant via an interconnected porosity, 
preferably in the 70–90% range and 200–600 µm in size [47, 173, 174].  
Micro-Computed Tomography (µ-CT) is a technique that allows reconstruction of 
3-D images of the developed scaffolds. A quantitative characterization of the micro-
structure of the scaffold has been performed from a µ-CT reconstruction. The images of 
the scaffolds, both in the dry and in the wet state are herewith reported in Figure 4-6. A 
highly porous and interconnected structure is apparent, which seem to preserve its 
fundamental features across the process of water swelling.  
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Wet State Dry State 
  
Figure 4-6 µCT images of the scaffold in the wet (left) and in the dry state (right). 
Different methods have been proposed, especially within bone research, to get 
more refined parameters from µ-CT images [202]. Here, a custom implementation of 
the standard histomorphometric parameters based on the parallel plate model [203] was 
used to achieve a quantification of the Trabecular Thickness (Tb.Th) and Trabecular 
Separation (Tb.Sp) [204]. This methodology revealed also that no isolated pores are 
present in the network. This result was achieved by means of a connected component-
labelling algorithm which counts the connected components. In this analysis the pores 
in contact with the REV margins were excluded.  
Numerical values of the pore size and morphology are comparable with those 
expected and present in the literature [179-180] and considered as optimal for cell 
ingrowth and migration, diffusion of nutrients and catabolite exchange. 
Nevertheless, scaffolds should act as cell support at the implantation site where 
molecular transport is dependent on vasculature growth and diffusion. Molecular 
transport would include the exchange of oxygen, nutrient, metabolic wastes and 
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molecular signalling. These biochemical exchanges are essential for cell migration and 
proliferation. Therefore, it is fundamental to evaluate the structural features of the 
constructs in wet conditions in order to guarantee a correct characterization. Table 4-2 
reports the numerical values of the quantitative analysis, based on the µ-CT data, on 
both dry and reswollen Alg/nHAp scaffolds.  
PARAMETERS UNIT 
DRY 
SCAFFOLD 
WET 
SCAFFOLD 
MATHIEU LM 
ET AL. 
Total Volume (TV) µm3 15.6±2.1 E9 18.8±1.5 E9 ___ 
Bone Volume (BV) µm3 3.2±0.7 E9 3.9±1.1 E9 ___ 
Bone Surface (BS) µm2 143.0±11.7 E6 115.0±9.1 E6 ___ 
Porosity (1-BV/TV) % 80.0±2.0 80.0±2.3 80.8÷87.8 
Trabecular Thickness 
(Tb.Th) 
µm 37.6±6.25 42.7±6.25 80÷130 
Trabecular Separation 
(Tb.Sp) 
µm 246.8±6.25 203.7±6.25 400÷1310 
Bone Surface to Total 
Volume (BS/TV) 
µm-1 9.2±1.1 E-3 6.1±1.3 E-3 25.2÷43.6 E-3 
Bone Surface to Bone 
Volume (BS/BV) 
µm-1 44.7±2.5 E-3 29.5±3.1 E-3 ___ 
Connectivity Density µm-1 5.4±0.9 E-3 4.9±1.1 E-3 ___ 
Table 4-2 Quantitative characterization of the Alg/nHAp scaffolds microstructure in Dry state and 
in Wet State compared to the literature values.  
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4.3.1 Reswelling Behaviour and in vitro Structural Stability 
Most natural polymers, including alginate, swell readily in biological fluids. It is 
of paramount importance for a scaffold intended to be used in tissue engineering 
protocol to keep its shape and mechanical stability for a time long, enough to allow the 
synthesis of a sufficient amount of extracellular matrix components by cells seeded. 
Moreover, an uncontrolled swelling would lead to loss of mechanical integrity and 
production of compressive stress toward the surrounding tissue. A set of experiments 
was performed to assess the structural stability as well as the ability of water uptake by 
the synthesized 3D structures. To mimic the conditions of a physiological environment, 
these measurements were carried out also in simulated body fluid (SBF). The time-
dependent swelling behaviours of composite scaffolds in water and SBF at room 
temperature are reported in Figure 4-7 A. The reswelling of the composite Alg/nHAp 
scaffolds did not significantly differ between water and SBF. As expected, in water the 
structure rapidly absorbed a high amount of solvent, reaching an equilibrium average 
swelling weight ratio of 1400% (w/w) within 5 min; after this time, no further 
significant increase in sample weight is observed. In SBF a first rapid step of solvent 
uptake can be observed within 5 min (up to 1200% of swelling weight ratio) followed 
by a very slow step of further hydration up to 1400% in the following 100 min. As it 
can be seen, there is a loss of mass of around 15% of weight in dynamic conditions in 
water [Figure 4-7 B]. This in vitro investigation was useful as a preliminary result to 
understand the dissolution behaviour of the scaffolds in reswollen conditions. Indeed, 
the effective dissolution of the construct must be tailored by means of in vivo studies in 
which the healing and regenerative processes are performed. As reported by Jones et al. 
[175] an ideal scaffold must “resorb at the same rate as the bone is repaired” therefore it 
is of paramount significance to investigate the dissolution of the construct when 
implanted in vivo. Anyway, this preliminary result allowed concluding that the construct 
has an intrinsic bias of dissolution in rehydrated conditions. Moreover, based on 
previous literature findings [164, 176-177], it is reasonable to predict that the 
dissolution rate will reach a plateau on in vitro conditions. 
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A  
B  
Figure 4-7:Reswelling behaviour and structural stability of Alg/nHAp scaffolds. A): Swelling ratio 
of scaffolds in deionized water and SBF; B): Dissolution behaviour of Alg/nHAp composite 
scaffolds. Loss of mass was calculated after 1, 2 3 and 4 weeks from immersion in deionized water.  
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4.4 In Vitro Cell Response 
Cell attachment, proliferation, and differentiation are the indication of cellular 
compatibility of the material and determine its suitability for tissue engineering 
applications. The attachment and growth of osteoblast-like cell lines on Alg/nHAp 
scaffolds were then assessed using MTS assay according to a protocol adjusted from the 
one provided by the manufacturer. Two human osteosarcoma cell lines were used, 
namely MG63 and Saos-2. Cells were seeded on the top of the scaffolds after reswelling 
of the structures at day 0 by means of DMEM medium; the assay was performed at days 
1, 7, 14 and 21 after initial seeding.  
 Both cell lines tested showed a good degree of proliferation after seeding onto 
the scaffolds; the main difference was the rate of growth displayed by the two cell lines. 
Figure 4-8 A and B reports the proliferation of MG63 and Saos-2 cell lines in 
Alg/nHAp scaffolds in comparison with nHAp-free scaffolds. This result demonstrates 
that nHAp, introduced into the scaffold to foster osteointegration, does not affect the 
adequacy of alginate to sustain cell proliferation. 
 The level of Alkaline Phosphatase activity (ALP) was also determined at 1 and 
21 days for both the cell lines with the aim to evaluate osteoblast functionality and/or 
differentiation processes during cell growth onto the scaffolds. Although the ALP 
activity detected was slightly higher at day 21 in comparison with day 1, this difference 
was not statistically significant (Figure 4-8 C). In particular, the expression level of 
ALP in MG63 cells, a partially undifferentiated cell line, remains low and does not 
show any statistically significant variation from day 1 to day 21, indicating that no 
differentiation process takes place in the scaffolds.  
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A  
B  
C  
Figure 4-8: Cell proliferation of Saos-2 (A) and MG-63 (B) cell lines as a function of time in 
Alg/nHAp and nHAp-free scaffolds. C): ALP activity level of MG63 and Saos-2 cells after 1 and 21 
days of culture in composite scaffolds.  
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 Individual cell morphology in Alg/nHAp composites was analyzed after 7 and 
21 days of growing using scanning electron microscopy (SEM).  
A  B  
C  D  
Figure 4-9: SEM micrographs of osteoblast-like cells seeded on Alg/nHAp scaffolds: MG63 cells on 
scaffold after 7 A) and 21 B) days of culture, Saos-2 cells on scaffold after 7 C) and 21 D) days of 
culture. 
Figure 4-9 reports SEM micrographs of osteoblast like cells MG63 and Saos-2 on 
the Alg/nHAp scaffolds after 7 and 21 days of culture. The majority of cells displayed a 
rounded morphology rather than a flat one and they appeared gathered together to form 
clusters, while the few others appear randomly attached on the material surface. The 
cells are well adherent to the pore walls with processes and multiple filopodia, 
surrounded by a network of fibrillar bundles of extracellular matrix particularly 
abundant after 21 days of culture. Cells can be found both on the pores localized on the 
top surface of the scaffolds and into the inner portions of the constructs. 
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4.5 Bioactive Chitlac/RGD-Scaffold  
Most biomaterials, especially that based on polymers, are able to adsorb non-
specifically proteins on their surface, by means of interactions at the protein/water and 
biomaterial/water interfaces. This “conditioning” film represents the substrate on which 
cells can easily adhere and migrate. The modification with specific proteins or peptides 
of the backbone of a polymer can be an effective strategy to tailor and control cell 
attachment, migration, proliferation and differentiation. Several proteins enhancing cell 
adhesion have been ionically or covalently attached to biomaterial surfaces to increase 
the amount of tissue regeneration [149-150]. Similarly, peptides can mimic the same 
response as a whole protein while being smaller, cheaper and less susceptible to 
degradation [149-150].  
When alginate scaffolds are used for cell transplantation it is often desirable to 
modify the scaffolds composition to promote cell attachment, as native alginate does not 
promote a significant adhesion. Mammalian cells do not have receptors for alginate 
polymers, which makes alginate scaffolds relatively inert [119]. One approach to 
promote cell adhesion is to introduce cellular adhesion molecules such as laminin, 
fibronectin, and collagen to scaffolds. However, coupling whole molecules can lead to 
non-specific interactions and the coupling is difficult to control. A variety of short 
amino acid sequences found in ECM molecules can mediate cell adhesion in place of 
the larger molecules, and these peptides can be coupled readily to polysaccharides. The 
fibronectin-derived adhesion peptide arginine-glycine-aspartic acid (RGD) and its 
subtypes are commonly used, as cell receptor-RGD interactions are well characterized.  
The identification of peptide sequences within ECM proteins that are responsible 
for cell adhesion led to the development of peptide-functionalized biomaterials. 
Incorporation of peptide motifs containing sequences that are recognized by integrin 
receptors, such as arginine-glycine-aspartic acid (RGD)-based sequences, are now a 
common strategy to enhance the mechanism as well as differentiation and proliferation 
of a variety of cells, including osteoblasts.  
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To introduce bioactive molecules enhancing the biological property of the 
scaffolds, Chitlac, a lactitolated-derivative of chitosan, was exploited as vector, after 
modification by chemical grafting of bioactive peptides (RGD). 
In this study, the chemical strategy employed for the conjugation of a RGD-
peptide (GRGDS) with the polycation Chitlac is based on amide bond formation (Figure 
4-10). Without performing any modification on Chitlac, the reaction was realized 
between the activated carboxylic acid groups of the peptide with the nucleophilic amino 
groups of the polycation. The strategy of carbodiimide chemistry was applied by 
activation of carboxylic group of peptide followed by grafting to Chitlac. 
 
Figure 4-10 structure of Chitlac-RGD obtained by GRGDS peptide conjugation to unmodified 
Chitlac.  
The so obtained Chitlac-RGD was used as a vector to introduce the bioactive 
signal into the scaffolds exploiting the electrostatic interaction between Chitlac 
(polycation) and Alginate (polyanion) 
The amount of Chitlac-RGD adsorbed on the scaffold was evaluated using by 
further labeling Chitlac with FITC. (Due to the very low degree of RGD substitution of 
  56 
Chitlac, the net charge of Chitlac-RGD can be considered to be roughly equivalent to 
that of Chitlac-FITC). The scaffolds were incubated with a solution of Chitlac-FITC and 
at defined intervals the solution was removed and the residual concentration of Chitlac 
in it was evaluated by means of spectrofluorimetry through a calibration curve (Figure 
4-11).  
 
Figure 4-11 Graphical representation of adsorption kinetic of Chitlac-FITC on each scaffold. The 
amount of adsorbed Chitlac in µg is reported as a function of time.  
The quantitative analysis shows that about 70% of Chitlac present in solution 
interacts with the scaffold in 60 minutes. After this time there is no more adsorption of 
Chitlac. It is possible to estimate that an average of 0.7µg of modified polysaccharide is 
adsorbed on each scaffold. 
The Chitlac-RGD modified scaffolds were then investigated to evaluate their 
bioactivity, cytocompatibility and biocompatibility. 
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4.6 In vitro bioactivity tests 
In addition to their structural function, scaffolds functionalized with RGD 
potentially provide cell adhesion signals allowing a more specific tailoring of cell 
response and tissue formation. The RGD-motif is able to promote selective attachment 
and migration of cell. It has been demonstrated that RGD peptides are able to improve 
also in vitro cell proliferation and differentiation of osteoblasts-like cells [101,102]. 
With the aim to evaluate the enhancement of bioactive properties derived by the 
introduction of Chitlac-RGD into the scaffolds, in vitro proliferation tests were 
performed using osteoblasts-like cells (MG63). Scaffolds based of Alg and nHAp 
without RGD-modification was used as control. The results obtained from the MTS 
assay are reported in Figure 4-12.  
 
Figure 4-12 Cell proliferation of MG-63 cell line as a function of time on Alg/nHAp composite 
scaffolds and on Chitlac-RGD composite scaffolds. MTS assay was performed at day 1, 7 and 14 
after initial seeding. 
It can be observed that on Chitlac-RGD scaffolds there is a significant increase 
of the total cell number from day 1 to 14 in comparison with non-functionalized ones, 
with a peak in the number of cells found at day 7 of culture. The proliferation rate of 
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cells seeded into Chitlac-RGD scaffold is at list twice that of cells seeded into 
Alg/nHAp scaffolds along the timeframe of the cell culture investigated.  
These results are consistent with the hypothesis that RGD adhesion peptide is 
able to enhance the bioactive properties of scaffolds.  
4.7  Antimicrobial Chitlac/nAg Scaffold 
The presence of a foreign body such as a synthetic biomaterial represents a 
potential site for microbial attachment. Reducing bacterial adhesion is important since 
microorganism surface attachment is the first critical step in the development of 
implant-associated infections. 
To overcome the limitations of antibiotic treatments for the prevention of 
periprosthetic infections, particular attention is devoted to the use of alternative 
antimicrobial agents as silver and antimicrobial peptides.  
In particular, thus the study has been focused on the development of Alg/nHAp 
scaffolds endowed with antimicrobial properties using a colloidal solution of Chitlac 
and silver nanoparticles (AgNPs). 
The decision to use this nano-silver colloidal system is based on the evidence 
that silver-based materials are generally considered good candidates for coating medical 
devices. Moreover, recent literature data deal with the preparation of nanocomposite-
coated materials based on polymers and silver nanoparticles [127]. Antimicrobial 
studies were carried out on a nanocomposite system based on Chitlac and AgNPs either 
as a colloidal solution or as hydrogels obtained in association with Alginate.   
The simple strategy used to embed Chitlac-nAg into the scaffolds exploits the 
electrostatic interaction between Chitlac and Alg as previously described for Chitlac-
RGD. The amount of silver nanoparticles presents into the scaffolds was evaluated by 
means of ICP. 
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4.8  Characterization of Alg/nHAp/nAg scaffolds  
Use of silver nanoparticles for control of implant-associated infection is a 
promising strategy. Literature data indicate that nAg in doses lower than 10 mg/kg is 
safe for biomedical application and it has no side-effects [181]. For these reason it was 
investigated the quantity of silver nanoparticles present in the Alg/nHAp/nAg scaffolds 
and the amount of release in a saline solution (0.15 M NaCl). 
The total amount of silver in the scaffold was evaluated by means of ICP-AES 
The organic components of scaffold was dissolved with a solution of aqua regia and the 
silver has been measured with a Spectroflame module E Optical plasma interface. The 
quantity of measured silver around 500 µg/g is reported in Figure 4-13 A. The graph are 
also reports the data obtained from the analysis of a scaffold without Chitlac nAg 
(negative control) and the theoretical total amount of silver that is the amount of silver 
contained in the solution in which the scaffold has been incubated. 
To investigate the silver release from the scaffolds, they were incubated in a 0.15 
M NaCl solution and the amount of silver in the supernatant has been measured at 
different times. The solution of NaCl was changed every 24 hours with the aim of 
maximising ion exchange. In the graph of figure 4-13 B is reported the quantity of 
residual silver present in the scaffold at different times. The release of the metal is 
gradual and after 216 hours (9days) almost all the silver is released in solution.  
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A  
B  
Figure 4-13 A) µg of silver per g of scaffolds; B) release of silver nanoparticles on the surrounding 
medium as function of time. 
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4.9 In vitro biocompatibility and bioactivity tests 
The citotoxicity of Alg/nHAp/nAg scaffolds was evaluated by MTS assay. The tests 
were performed using two different osteoblasts-like cells line: MG-63 and Saos-2. The 
results were compared with that obtained from Alg/nHAp control scaffolds. The Figure 
4-14 summarizes the results:  the proliferation rate of cells seeded into Alg/Hap/nAg 
scaffolds compared with that one of cells on Alg/nHAp scaffolds is equal. The presence 
of silver nanoparticles does not impair the biocompatibility of the scaffolds. 
A 
 
B 
 
Figure 4-14 Proliferation rate of A) Saos-2 cell line, B) MG-63 cell line. 
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In order to evaluate the antimicrobial activity of the Chitlac-nAg scaffolds, both 
Gram+ and Gram– strains were considered. The antimicrobial activity of 
Alg/nHAp/nAg scaffolds was tested on four different bacteria strains: Escherichia coli 
(ATCC 25922), Pseudomonas aeruginosa (ATCC 27853), Staphylococcus aureus 
(ATCC 25923) and a clinical strain of Staphylococcus epidermidis. These strains were 
selected because of their occurrence in biomaterial-related infection [103]. More than 
the 50% of perimplant infection is caused by S. epidermidis [104]. On the other hand E. 
coli is the typical bacterium to evaluate the efficacy of antimicrobial agent and 
antibiotics. 
The time killing assay was performed incubating 1 ml of bacteria suspension (106 
CFU/ml) with the scaffolds and evaluating at different time, after seeding in solid 
medium, the amount of vital bacteria (CFU/ml) present in the solution. The test was 
performed in shaking condition maximizing the direct contact between bacteria and 
silver nanoparticles. The results were compared with those obtained by the tests 
performed with Alg/nHAp scaffolds without nAg and with a solution of bacteria growth 
in liquid medium (control). Overall, Alg/nHAp/nAg scaffolds showed a remarkable 
bactericidal effect against all four bacterial strains with a very fast killing kinetics. The 
results are reported in Figure 4-15.  
Graph A shows the results obtained by P.aeruginosa. Already after 30 minutes it is 
possible to observe a little decrease of the CFU/ml; after 180 minutes can be observed a 
drastically drop of almost three orders of magnitude in the CFU/ml can be observed, 
while Alg/nHAp does not display any antibacterial activity. After 300 minutes there is 
an almost complete bacterial inactivation. 
In the case of E. coli (graph B) the bactericidal activity of the nanoparticles is 
comparable with that observed for P. aeruginosa. After 180 minutes there is a reduction 
of 4 log units in CFU/ml and after 300 minutes complete inactivation of bacterial cells 
was found (a drop of 8 log units in CFU/ml). 
In the case of the strain of S. aureus (graph C) after 180 minutes the decrease of 
CFU/ml is 1,5-2 log units. After 300 minutes the bactericidal activity results more 
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evident, in fact, it is possible to observe a decrease of 7 log units in CFU/ml with 
respect to control. 
The results of killing kinetics of S. epidermidis is reported in graph D. For this 
strain, the decrease in CFU/ml became remarkable (2-3 log units) only after 180 
minutes of incubation with scaffolds.  After 300 minutes the bactericidal activity led to 
a drop of 3-4 log units in CFU/ml. 
A  C  
B  D  
Figure 4-15 Time killing assays of different bacteria strains seeded on Alg/nHAp/nAg scaffolds, 
Alg/nHAp scaffolds  and of bacteria grown in liquid broth (control). A) Pseudomonas aeruginosa 
(ATCC 27853); B) Escherichia coli (ATCC 25922); C) Staphylococcus aureus (ATCC 25923) D) 
clinical strain of Staphylococcus epidermidis. 
As a whole the obtained results show that silver nanoparticles confer to 
composite scaffolds good antimicrobial properties, without being harmful to 
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mammalian cells. Considering the fact that in prosthesis implantation, the surgery is 
always associated with antibiotic prophylaxis, the combined use of antimicrobial 
scaffolds and antibiotics should drastically decrease the risk of infection.  
4.10 In vivo tests  
In the field of regenerative medicine the identification of optimal biomaterial 
scaffolds is strictly related with the architecture design, composition and biomaterial 
tissue interactions. In order to evaluate the osteoinductive, osteoconductive and 
osteointegration properties of scaffolds, in vivo tests were performed on rabbit models. 
Freeze-dried scaffolds were used to fill non-critical defects surgically created in the 
distal femur diaphysis. PerioGlas® and empty defects were used as positive and 
negative controls, respectively. The implanted bone substitutes were dissected after 6 
weeks and three different analyses were performed on ex vivo samples to provide an 
effective qualitative assessment of scaffold performance in vivo. The methodologies 
used to investigate the in vivo properties of scaffolds were: Micro Computed 
Tomography (µ-CT), optical microscopy, and Confocal Laser Scanning Microscopy 
(CLSM).  
The results were considered in relation to the main properties that a scaffold 
should have: osteoinductivity, osteoconductivity and osteointegration.  
µ-CT scanning allowed observation of the features of the scaffold inside the 
defect in the whole specimen (see Figure 4-16). In µ-CT slices, three different opacities 
(grey levels) related to the three different components of the image (except for the black 
background). The darker grey belongs to the part of the scaffolds that is still intact; the 
lighter grey represents the cortical bone, whereas the intermediate grey corresponds to 
newly formed bone. Comparing the different simple it is possible to evaluate the 
different level of integration of material. Figure 4-16 reports the sagittal and coronal 
central slice of the defects. Comparing the different sample with the control material 
(BAG) is possible to establish the level of integration and degradation of composite 
materials and the advantage derived by the use of scaffold. The µCT results confirm the 
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preliminary results obtained from visual observation. For all sample no formation of 
fibrous capsule or inflammatory tissue was observed.  
In the case of defect filled with BAG the µCT section (Figure 4-16 B) shows 
regenerative process mainly derived from the migration of precursors cell from 
periosteum to the inner part of scaffold. In fact, the newly formed mineralized matrix is 
massively present in the periphery of the defect, permeating in the inner part of the 
defect on the medial region of cortical bone. In the medullary interface of cortical bone 
the deposition of mineralized matrix is not appreciable suggesting that these material is 
not able to induce migration of medullary precursor able to completely restore the 
geometry of native cortical bone. Furthermore debris of BAG are still present in the 
defect area surrounded by new matrix suggesting that the degradation rate of BAG is 
not synchronous to matrix deposition rate.  
The pathway of regeneration observed in the case of Alg/Hap (Figure 4-16 C) 
scaffolds paralles the one observed for the BAG material. There is centripetal deposition 
of mineralized matrix, both on the surface and into the porous structure of the construct, 
due to the migration of cells from the periosteum. In the bone marrow region, where the 
scaffold is still present, it is possible to detect migration of cells and deposition of 
mineralized matrix derived by the differentiation of medullary precursors.  
  As for Alg/nHAp constructs, in Alg/nHAp/RGD scaffolds (Figure 4-16 D) both 
medullary precursors and cells from periosteum are involved in the regenerative 
process. In this case can be observed a completely restore of the geometry of cortical 
bone. The amount of deposition of mineralized matrix is able to replace the scaffold and 
completely fill the defect. The edge of cortical newly bone evidence a higher amount of 
mineral suggesting the presence of a remodelling process with formation of cortical 
lamellar bone. In the medullary portion of cortical bone the remodelling process is not 
concluded but the defect is completely filled.  
The main aim of in vivo study with Alg/nHAp/nAg scaffolds was to evaluate the 
effects of antimicrobial agents on the regenerative ability of Alg/nHAp scaffolds. The 
results (Figure 4-16 E) show that the presence of nAg into the scaffold slightly delays 
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the healing rate, without inducing foreign body reaction. In fact, there is not formation 
of fibrous capsula around the scaffold, and deposition of mineralized matrix can be 
detected on the surface and in the periphery of the porous structure. These results 
suggest that nAg affects the osteoinductive and ostecondutive properties of Alg/nHAp 
scaffolds but does not compromise the cytocompatybility of composite.  
 µCT slice of sagittal view µCT slice of coronal view 
Empty Control  
 
 
BAG  
 
 
Alg/nHAp  
 
 
C1 
C2 
B2 
B1 
A1 
A2 
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Figure 4-16 µ-CT sagittal (1) and coronal (2) sections after 5 weeks from implantation with: A) 
control femur: without implant (Magnification 2.5x) B) BAG scaffold used as commercial 
reference (Magnification 2.5x); C) Alg/nHAp scaffold (Magnification 3x); 
Alg/nHAp/RGD  
 
 
Alg/nHAp/nAg  
 
 
Figure 4-16 µ-CT sagittal (1) and coronal (2) sections after 6 weeks from implantation with: D) 
RGD scaffold investigated as bioactive material (Magnification 3x); E) nAg antimicrobial scaffold 
(Magnification 3x) 
4.10.1 Histological Analysis 
Histology is the standard method to evaluate host tissue reaction to biomaterials 
and ECM formation within the interconnected pores of scaffolds. The histological 
analysis was performed both in mineralized and demineralized tissue. Representative 
histological images are showed in Figure 4-17. The results obtained from the analysis of 
mineralized tissue allow an overview of the sample obtained from dissection of the 
femur 6 weeks after surgery. It is possible, by through histological analysis on 
mineralized samples, to evaluate the nature of the mineralized matrix and the level of 
modeling of bone tissue. The image of empty control (Figure 4-17 A) shows continuity 
between the new mineralized matrix and the native bone. The newly formed tissue is 
mature non-lamellar bone in which osteoblasts are completely surrounded by new 
D1 
D2 
E1 
E2 
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deposed matrix, but they are not organized in the typical lamellar structure of cortical 
bone.  
Deposition of bone mineralized matrix is observed in the defect treated with 
BAG (figure 4-17 B), but there is still the presence of BAG debris into the newly 
formed bone tissue. The matrix was deposed all around the biomaterial which results 
entrapped into the new bone. These results confirm the high biocompatibility of BAG 
but they also show that the rate of degradation of glass is not comparable with the rate 
of deposition of bone matrix. The defect can not be considered completely healed 
because there is still biomaterial that must be replaced by native bone. 
The images collected for the sample with Alg/nHAp (Figure 4-17 C) shows 
deposition of mineralized matrix into the porous structure. In the peripheral region of 
the defect, the scaffold is completely substituted by newly formed bone which appears 
mineralized also at the interface between native bone and residual implant. Similar 
results are observed for the defect filled with Alg/nHAp/nAg scaffold (Figure 4-17 E). 
Deposition of new matrix takes place into the porous structure and there is continuity 
between the native bone and the newly-formed one. In the same images it is possible to 
observe the modeling processes with the formation of osteons.  
In the case of sample with RGD (Figure 4-17 D) it is possible to observe a 
notable deposition of mineralized matrix remodeled at the edge of cortical bone, and not 
completely remodeled in the inner part of the defect. There is continuity between the 
scaffold and the native bone, the cells migrate into the scaffold deposing mineralized 
matrix also in the inner part of scaffold. The modeling processes started in the external 
portions of the defect; in these regions it is possible to observe same osteoic structures. 
In the inner part of scaffold the mineralized matrix is not still modeled but it is a 
mineralized matrix derived from an osteoid tissue as result of an uncompleted 
remodeling process. 
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Figure 4-17 A Light microscopy image of control femur: without implant (Magnification 20x)  
 
  
Figure 4-17 B Light microscopy image: BAG scaffold used as commercial reference (Magnification 
20x  
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Figure 4-17 C Light microscopy imageAlg/nHAp scaffold (Magnification 20x  
 
  
Figure 4-17 D Light microscopy image RGD scaffold investigated as bioactive material 
(Magnification 20x)  
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 Figure 4-17 E Light microscopy image: nAg antimicrobial scaffold (Magnification 20x)  
For the Alg/nHAp scaffolds it was possible to perform also the demineralized 
histology. Histological analyses are reported in the figures hereafter.  
Figure 4-18 shows the interface between cortical bone and scaffold. Newly 
formed lamellar bone is visible, between the newly formed tissue and the native one can 
be observed integration suggesting a complete fusion between implant and bone. The 
newly deposited matrix presents the typical organization of mature bone with osteocyte 
located in lacunae surrounded by mineralized matrix. Moreover, in figure 4-19 the 
presence of osteoclasts reveals the active nature of the newly deposited bone. These 
giant multinucleated cells are responsible for bone resorption and their presence ensures 
bone remodelling. 
Figure 4-20 shows a normally structured bone marrow (with the presence of a lot 
of adipocytes, hemopoietic tissue cellularity and blood vessels), the inner aspect of 
which is lined by one superimposed osteoid-like layers; in addition, at the top of the 
inner one, considerable lamellar bone is present.  
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  72 
In figure 4-21, the presence of osteoblasts along osteoid-like matrix is consistent 
with active bone formation. Blood vessels and osteoclast presence was observed in 
several areas of the colonized scaffold (Figure 4-21) closely associated to scaffold 
residues. 
 
Figure 4-18 Hematoxylin and Eosin staining at the interface between scaffold and bone: presence of 
mature lamellar bone within the interposing connective tissue Original magnification:10x. 
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Figure 4-19: Alcian Blue staining plus Hematoxylin and Eosin counterstaining evidence osteoclasts 
and new bone formation. Original magnification: 50x. 
Osteoclast 
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Figure 4-20 Alcian Blue staining showing the appearance of two osteoid-like layers at the left aspect 
bone marrow facing the void left by EDTA-induced scaffold loss. Original magnification: 10x. 
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Figure 4-21: Hematoxylin and Eosin staining at the intracortical scaffold core. Original 
magnification: 10x. 
4.10.2 In vivo Fluorochrome Labelling   
Fluorochrome labelling reported in Figure 4-22 shows the kinetics of bone 
deposition during the healing period. The three different stains were able to bind the 
sites were the calcification process occurred. The fluorochromes were administrated 
systematically every 7 days starting at day 14 from scaffold’s implantation. Filters sets 
for confocal fluorescence microscopy were chosen either for selective excitation of 
single fluorochrome. Due to their feature of chelating their active iminodiacetic groups 
with the apatite of the bone matrix, the dyes were used to label bone formation both in 
the scaffold’s network and at the edges of the cortical bone. The presence of 
fluorochromes in the images indicates site, time and amount of deposition and enhances 
the information contained in the bone specimen.  
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Figure 4-22 fluorochromes labelling results 
The three different fluorochromes administrated, distinguishable by the pseudo-
color assigned during the scanning acquisition, are reported in the five different images 
of Figure 4-22. These images indicate that the bone deposition is constant during the 
healing time. The higher amount of deposition is observed at week 4 but it is anyway 
comparable with the other images. The data also shows that at the third week the major 
amount of mineralized matrix is already present, and that in the tissue surrounding 
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osteoblasts the remodeling process has started. In the case of the scaffold decorated with 
RGD the kinetics of matrix deposition confirms the suggestion of µCT; in fact, the 
remodeling process is complete at the edge of cortical bone and in the medullar 
interface the matrix mineralized is still incompletely organized. For the other scaffold 
the amount of mineralized matrix is lower and the remodeling process has the same rate 
in the all newly deposed bone. 
4.11 In vivo antimicrobial animal model 
Infection associated with biomaterial represents a significant challenge to the 
widespread application of medical implants. The presence of a foreign body such as a 
synthetic biomaterial represents a potential site for microbial attachment. Biofilm 
formation on surfaces is an ancient strategy for bacterial survival. Billions of years of 
adaptation provide microbes with the ability to colonize any surface, including those 
used in orthopedic surgery. Although remarkable progresses have been made in the 
treatment of orthopedic diseases with implanted prostheses, infection rates remain 
between 1% and 2%, and are higher for revision surgeries. Over the past few decades, 
many attempts have been made to prevent and cure orthopaedic implant infections by 
incorporating antibiotics in polymethylmethacrylate bone cements, in primary and 
revision surgery. However, the clinical efficacy of antibiotic-releasing bone cements is 
not widely accepted and the long-term exposure to low doses of antibiotic are strongly 
correlated with the emerging threat of antibiotic resistance in medicine. The composite 
scaffolds modified with nAg were tested in vitro and it has shown to present promising 
antimicrobial activity without harming eukaryotic cells. After the in vitro study it 
becomes mandatory to identify the optimal animal model to be used for the in vivo test. 
In 1983 Fitzgerard [189] proposed a canine animal model of osteomyelitis; this animal 
model, in 2004, was extended to rabbits by Koort et al. [190] they also introduce the 
PET scan analysis as methodologies to investigate infection. 
 The aim of the last part of the study was to individuate an animal model to be 
used for the investigation of the efficacy of Alg/nHAp/nAg scaffolds in preventing 
implant infections. 
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Figure 4-23 A) 3D reconstruction of bone tissue; B) PET scan slices of infected animal; C) 3D 
reconstruction of bone tissue of a uninfected control animal; D) PET scan slices of uninfected 
animal; E) 3D reconstruction of fractured bone tissue; F) PET scan slices of fracture 
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During infection mononuclear cells and granulocytes intensively use glucose. 
Administering 18F-FDG it becames possible to measure the glucose metabolism at the 
infection site. The main problem associated with the use of PET is that an inflammatory 
phase is associated with the first stage of bone healing an inflammatory phase is 
associated. The inflammatory processes induce high metabolism activation and glucose 
consume by the cells, in a similar way of infection.  
This consideration becomes the starting point for planning the animal tests. The 
animal model chosen was rat and the surgery protocols used was the same described by 
Koort [190]. The PET scan was performed four weeks after surgery, this range of time 
is necessary both for the development of infection and for the overcome of the early 
stage healing processes in rats.  
 Comparing the collected data of PET scans with the ones obtained by CT scan 
it was possible to determinate the aetiology of the enhanced metabolism of glucose. In 
fact, in case of fracture inflammatory cells are involved, responding in PET analysis in a 
similar way as in the case of infection. Hence µCT allows to exclude the case of 
enhanced metabolism induced by fracture (Figure 4-23 A, C). It is possible to indicate 
that, in case of structurally intact bone, the enhanced metabolism of glucose is strictly 
related with infection (Figure 4-23 E and F). 
Comparing the activities detected in infected animals with the negative controls 
it is possible to notice that glucose metabolism at the infection site has a value that is 
twice with respect to the value of negative control (Figure 4-23 B, D). 
The microbiology analysis, performed at the department of microbiology of 
Turku university, confirm the presence of infection, both in the sample collected from 
the tissue surrounding the defect and the cement culture.  
This preliminary pilot study suggest that microbiologic analysis associate with 
PET scan as methodologies of investigation, is an opportune model of Osteomyelitis to 
evaluate the antimicrobial properties of scaffolds modified with nano-silver to 
investigate their properties in vivo. 
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5 Conclusion 
The first part of the work dealt with the development and characterization of 
composite scaffolds based on Alg and nHAp. The characterization of the single 
components of the structure, Alg and nHAp, allowed retaining these two constituents as 
suitable for the aim settled The casting strategy exploited a novel method based on the 
sequential (I) formation of a homogeneous gel stabilized by calcium ions uniformly 
released from a nHAp reservoir; (II) freeze-casting of the gel, which allowed to obtain 
macroporous interconnected scaffolds. A detailed morphological analysis of the final 
3D structure revealed an interconnected and isotropic pore network with a range of pore 
size considered optimal to obtain good osteointegration and osteoconduction. 
Compressive tests indicated that addition of nHAp induces a remarkable increase of 
mechanical features of composites when compared to those of pure alginate scaffolds. 
The composite scaffolds display a high structural wettability and stability both in water 
and in physiological solutions. 
Cytocompatibility tests allowed to evaluate cells attachment and penetration 
leading to conclude that the scaffold sustain efficiently osteoblast proliferation in vitro. 
Cell morphology, viability and proliferation were examined.  
Alg/nHAp scaffolds were coated with Chitlac-RGD to induce a specific cell 
reaction.Biological in vitro tests were performed on such modified scaffolds showed 
good cytocompatibility and improved cell proliferation. 
Infection associated with biomaterial represents a significant challenge to the 
more widespread application of medical implants. The presence of a foreign body such 
as a synthetic biomaterial represents a potential site for microbial attachment.  
To overcome the limitation of the antibiotic treatment particular attention was 
focused on the use of silver and peptides as antimicrobial agents. Silver-based materials 
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are generally considered good candidates for coating medical devices and recent 
literature data deal with the preparation of nanocomposite-coated materials based on 
polymers and silver nanoparticles. Antimicrobial studies were carried out on a 
nanocomposite systems based on lactose-modified chitosan (Chitlac) and AgNPs either 
as a colloidal solution or embedded into alginate scaffolds. In both cases the materials 
displayed a remarkable bactericidal effect on four types of bacteria strains: S. 
epidermidis, E. coli, S. aureus, and P. aeruginosa.  The composite also does not shows 
toxicity effects against human cells MG63 and Saos. The scaffolds modified with silver 
nanoparticles show promising in vitro antibacterial activity against almost all the main 
pathogens associated with implant related infection. The scaffolds are optimal candidate 
for prevent the infection. However, more studies concerning in vivo antimicrobial 
properties are needed 
In conclusion, the developed scaffolds have suitable biological properties both 
bioactive and antimicrobial. The in vitro results showed a high level of citocompatibility 
for all the scaffolds studied even in the presence of Chitlac-nAg does not compromise 
the compatibility of scaffolds. In the case of scaffolds modified with RGD the results 
confirm that the presence of bioactive molecule is able to enhance the healing process 
since high osteoconduction and osteinduction properties are observed. The scaffolds are 
able to enhance the regenerative process also compared with the spontaneous healing 
process that occurs in non-critical defect.  
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